Wayne State University

DigitalCommons@WayneState
Wayne State University Theses

1-1-2012

Disrupting cxcr2 macromolecular complex pdzdomain interactions during inflammatory
chemotaxis
Marcello Castelvetere
Wayne State University,

Follow this and additional works at: http://digitalcommons.wayne.edu/oa_theses
Recommended Citation
Castelvetere, Marcello, "Disrupting cxcr2 macromolecular complex pdz-domain interactions during inflammatory chemotaxis"
(2012). Wayne State University Theses. Paper 172.

This Open Access Thesis is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne
State University Theses by an authorized administrator of DigitalCommons@WayneState.

DISRUPTING CXCR2 MACROMOLECULAR COMPLEX PDZ-DOMAIN
INTERACTIONS DURING INFLAMMATORY CHEMOTAXIS
by
MARCELLO P. CASTELVETERE
THESIS
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
MASTER OF SCIENCE
2012
MAJOR: BIOCHEMISTRY AND MOLECULAR
BIOLOGY
Approved by:

_____________________________________
Advisor

Date

© COPYRIGHT BY
MARCELLO P. CASTELVETERE
2012
All Rights Reserved

DEDICATION

I dedicate this work to my family and Natasha,
for all their support.

ii

ACKNOWLEDGMENTS

I would like to thank the following people who, through collaboration, thoughtful advice,
instruction, or patience, have helped me along the way:
Advisor: Dr. Chunying Li
Thesis committee members: Dr. David Evans and Dr. Ladislau Kovari
Laboratory colleagues: Yanning

u Shuo Wang, Yuning Hou and Xiaoqing Guan

The Biochemistry Department at Wayne State Universities School of Medicine

iii

TABLE OF CONTENTS
Dedication

…………………………………………………………………………….…ii

Acknowledgements

…………………………………………………………….…iii

List of Tables

…………………………………………………………………….…vii

List of Figures

……………………………………………………………………….viii

Chapter 1 Introduction

………………………………………………………………1

1.1 Neutrophils

………………………………………………………………1

1.2 Chemokines, IL-8

………………………………………………………2

1.3 CXCR2, an IL-8 Receptor
1.4 G-protein Signaling

………………………………………………4

…………….……………………...…………………5

1.5 CXCR2 Contains a PDZ-motif
1.6 NHERF1 Binds CXCR2

…...…………….……………………8
………………………………………………10

1.7 PLCβ2, CXCR2’s Downstream Effector

………………………………13

1.8 Chemokine Signaling Triggers Chemotaxis
1.9 CXCR2 Modulators

………………………………………………………19

1.10 Formation of the Uropod
1.11 A Means to an End

………………...….…15

……………………………………….……...20

………………………………………………….…...21

1.12 Summary of IL-8 Migration ……………………………………….…...…22
Chapter 2 Materials & Methods

……………………………………..………………..25

2.1 Antibodies and Reagents

………………………………………………25

2.2 Plasmids, Cloning, and Mutagenesis

………………………………25

2.3 Cell Culture and Transfection ………………………………………………26
2.4 Human Neutrophil Isolation from Buffy Coats

iv

………………………26

2.5 Murine Neutrophil Isolation from Mouse Bone Marrow
2.6 Western Blots

………………27

………………………………………………………………27

2.7 Pulldown Assay

……………………………………………………...28

2.8 Pairwise Binding

……..……………………………………………….29

2.9 Macromolecular Complex Assembly ………………………………………29
2.10 Co-immunoprecipitation

………………………………………………29

2.11 CXCR2 Peptide in Vitro Competitive Binding

………………………30

2.12 CXCR2 Degradation ………………………………………………………30
2.13 Zigmond Migration Chamber ………………………………………………31
2.14 Statistical Analysis

………………………………………………………32

Chapter 3 Results ………………………………………………………………………33
3.1 HL-60 Differentiation

………………………………………………………33

3.2 Human Neutrophils and dHL-60 Cells
3.3 Biochemical Assay Results

………………………………………………36

3.4 CXCR2 C-terminal Synthetic Peptide
3.5 CXCR2 Degradation

………………………………34

………………………………42

………………………………………………………43

3.6 Migration Introduction ………………………………………………………46
3.7 Distance Traveled
3.8 Directness

………………………………………………………48

………………………………………………………………53

3.9 Forward Migration Index

………………………………………………56

3.10 FMI Through Time

………………………………………………………59

3.11 Sector Maximum

………………………………………………………61

3.12 Rose Diagram ………………………………………………………………64

v

3.13 Center of Mass

………………………………………………………66

3.14 Rayleigh Test ………………………………………………………………68
Chapter 4 Discussion

………………………………………………………………70

4.1 Conclusion of Biochemical Data

………………………………………70

4.2 Conclusion of Migrational Data

………………………………………72

4.3 Thoughts

………………………………………………………………74

4.4 Future Directions
References
Abstract

………………………………………………………75

………………………………………………………………………77
………………………………………………………………………………100

Autobiographical Statement

………………………………………………………101

vi

LIST OF TABLES
Table 3.1 Distances Traveled

…………………………………………………….…50

Table 3.2 Distances Traveled Vs. Controls
Table 3.3 Directness

……………………………………………………….………53

Table 3.4 Average Directness
Table 3.5 Endpoint FMI’s

………………………………………………….……56

………………………………………………………………58

Table 3.6 COM Distance from Origin
Table 3.7 Rayleigh Test

…………………………………….…52

……………………….………………………67

…………………………………………………….…………69

vii

LIST OF FIGURES
Figure 1.1 CXCR2 is a GPCR

…………………………………………………….…7

Figure 1.2 NHERF1 PDZ Domain-motif Interactions
Figure 1.3 Activation of PLCβ2

…………………………………………………….…14

Figure 1.4 PIP3 Dictates Cellular Polarization
Figure 2.1 Zigmond Chamber

…………………………….…12

…………………………………….…24

…………………………………………………….…32

Figure 3.1 dHL-60 Expression of NHERF and PLC Isoforms …………………….…35
Figure 3.2 CXCR2 Interacts with NHERF

…………………………………….…37

Figure 3.3 PLCβ Isoforms Interact with NHERF

…………………………….…39

Figure 3.4 Macromolecular Complex Formation

…………………………….…41

Figure 3.5 CXCR2 C-tail Peptide

…………………………………………….…42

Figure 3.6 NHERF1 Nucleates CXCR2 and PLCβ2

…………………………….…43

Figure 3.7 CXCR2 Degradation

…………………………………………………….…45

Figure 3.8 Distances Defined

…………………………………………………….…48

Figure 3.9 Directness Vs. Time

…………………………………………………….…54

Figure 3.10 Forward Migration Indexes Defined

…………………………….…57

Figure 3.11 Average FMI’s

…………………………………………………….…58

Figure 3.12 X-FMI Vs. Time

…………………………………………………….…60

Figure 3.13 Y-FMI Vs. Time

…………………………………………………….…61

Figure 3.14 Sector Maximum

…………………………………………………….…63

Figure 3.15 Rose Diagrams

…………………………………………………….…65

Figure 3.16 Center of Mass Vs. Time

…………………………………………….…66

viii

1

CHAPTER 1
INTRODUCTION
1.1 Neutrophils
The human body is prone to attacks from a host of pathogens and underlying all
bodily defense is a strong immune response. As a result, immune systems are under a
constant state of surveillance and pathogen elimination. Immune cells must act fast and
efficiently to combat illness and circulating neutrophils represent the body’s first line of
defense. Neutrophils are the most abundant inflammatory cell type and account for 6070% of white blood cells in circulation (5x109 cells per liter) [3]. In the early stages of
acute inflammation neutrophils are recruited in great numbers to initiate an immune
response. They are short lived, averaging a 4-5 day lifespan and once they complete
their immunological duties are recycled by host macrophages [4].
Neutrophils play a vital role in host defense, and once stimulated, change from a
relatively unanimated circulatory state to an aggressively invading immune cell. As
neutrophils circulate through blood vessels they may encounter inflammatory signals
attached to endothelial cells by heparin sulfates [5]. These signals activate receptors on
the neutrophils which cause them to immediately arrest themselves on endothelial cells,
alter

their

shape

becoming

polarized,

activate

migratory

enzymes,

perform

extravasation of the blood vessel, demonstrate directed movement toward inflammation,
and carry out a respiratory burst [6]. These changes in behavior are ultimately due to
inflammatory signals, such as chemokines, binding to their cognate cellular receptors,
thus beginning an intracellular signaling cascade [7, 8]. Infiltration of inflamed tissue is
imperative to host defense, yet the uncontrolled invasion of leukocytes is responsible for
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a variety of pathological conditions, including rheumatoid arthritis, ischemia-reperfusion
injury, arteriosclerosis, virus-induced myocarditis, psoriasis, and allergic reactions [9].
Neutrophils migrate through the body’s extracellular matrix to sites of
inflammation, where they establish an important source of cytokines or other immune
factors and have a defining role in the outcome of the inflammatory state [10]. As
leukocytes migrate they express the necessary proteins to adhere to a variety of
extracellular matrix macromolecules, such as laminins, collagens and fibronectin [11].
Chemoattractants, produced from microorganisms, necrotic, stromal, epithelial, and
other cells present during inflammation, also bind to extracellular matrix elements due to
their negative charges. The chemoattractants diffuse away from their source of origin,
forming a gradient, casusing neutrophils to respond by migrating up the gradient
towards the inflamed tissue [12]. Neutrophils can sense shallow gradients of
chemoattractant, while remaining stationary, which is essential for navigation through
crowded areas [13]. Interleukin-8 (IL-8), a strong activator of neutrophils, is one such
chemoattractant involved in inflammation and requisition of neutrophils to sites of injury
or infection [14].

1.2 Chemokines, IL-8
Chemokines are a class of small chemotactic cytokines, roughly ten kilo-Dalton
globular proteins, that signal to cells through seven-transmembrane G-protein coupled
receptors (GPCRs) located in the cellular membrane. Chemokines have four
characteristic cysteines, and are classified based on the arrangement of the first two
cysteines, they are C, CC, CXC, and CX3C (X being any amino acid) [15]. The
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chemokine receptors are named by the chemokine class they bind, for example CCR1
through CCR9 bind CC chemokines and CXCR1 through CXCR7 bind CXC
chemokines. Chemokines are involved in numerous biological processes such as
inflammation, cell recruitment, wound healing, tumor growth, metastasis, angiogenesis
or angiostasis, and lymphoid development. For a review of chemokines and their
functions see [16].
One subtype of CXC chemokines, which possess the ELR (glutamic acid –
leucine - arginine) amino acid motif, increase angiogenic effects in endothelial cells and
are important in regulation of chronic inflammatory diseases [17]. ELR-CXC chemokines
are also involved in neutrophil signaling by binding to their cognate receptors, CXCR1
and CXCR2 (CXC chemokine receptor 1 and 2), which stimulates an inflammatory
response through intracellular G-protein signaling cascades and signal amplification
[18]. Evidence of ELR’s importance in chemotactic signaling has been verified, as the
ELR motif is required for IL-8 to mount a proper inflammatory response, and mutation of
the ELR’s arginine residue abolishes binding to CXCR2 [19]. It is also worthy to mention
the ELR motif is present on seven of the 17 total CXC chemokines, and all seven are
neutrophil activating chemokines, having a high affinity for CXCR2 [20].
All ELR CXC chemokines are neutrophil chemoattractants and induce
chemotaxis, cellular polarization, intracellular [Ca2+] release, bioactive lipid production,
activation of adhesion proteins, granule exocytosis, and the respiratory burst associated
with neutrophils’ antimicrobial effects. These ELR-CXC chemokines play a direct role in
chronic inflammatory diseases and inflammatory responses [21]. Of the ELR containing
CXC chemokines IL-8 (CXCL8) has been firmly established as a pro-inflammatory
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chemokine. Biologically active IL-8 is released by a variety of cell types, such as
epithelial cells, endothelial cells, fibroblasts, keratinocytes, synovial cells, chondrocytes,
macrophages, cells surrounding a necrotic focus, as well as many tumor cells, and it
mediates a potent response in neutrophils by binding to CXCR2 [7, 22, 23]. IL-8 is
generated as a 99-amino acid precursor protein, and after a cleavage of a 20 residue
leader sequence it is released extracellularly. In its mature form IL-8 consists of 72
amino acids and a heparin-binding domain. Processing of IL-8 greatly increases its
biological activity, making this peptide one of the most potent chemoattractants for
neutrophils [20, 24-26].

1.3 CXCR2, an IL-8 Receptor
Two different ELR chemokine receptors on neutrophils, CXCR1 and CXCR2,
both bind to IL-8 [23, 27]. These two receptors share a 77% sequence identity, with two
blocks containing a particularly high rate of conservation, and both genes are colocalized on chromosome 2q35 [28, 29]. CXCR2 has a high affinity for IL-8 as well as
other members of the ELR-CXC chemokine family (e.g., CXCL1 or MGSA/GROα,
CXCL5 or ENA-78, and CXCL7 or NAP-2), whereas CXCR1 has a high affinity for IL-8
only [22, 30]. Stimulation of either receptor triggers an increase in cytosolic [Ca2+],
chemotaxis, and granule exocytosis [31, 32].
Despite their similarities, CXCR1 and CXCR2 differ in how they transduce the IL8 signal, ultimately creating different functional outcomes and behaviors. One example,
is phospholipase D (PLD) activation and the respiratory burst are only triggered by
CXCR1 activation, which indicates CXCR1 and CXCR2 function independently of each
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other. Studies have also confirmed CXCR2, and not CXCR1, is the primary chemokine
receptor required in mediating cellular chemotaxis in endothelial cells and neutrophils
[33-35]. Furthermore, CXCR2 is able to actively respond to IL-8 at much lower
concentrations. This evidence points to CXCR2 being used as a long-range
chemoattractant receptor when IL-8 concentration is low, and as chemokine levels
increase near the site of inflammation, CXCR1 will begin PLD activation and respiratory
burst, causing tissue damage [36, 37].
Many unique proteins have been identified that associate with CXCR2, either in
its unstimulated state (11 proteins), stimulated (7 proteins), or both (6 proteins) [38].
These proteins are thought to act as part of a CXCR2 chemosynapse, regulating the
function of CXCR2 and mediating signal transduction by activating and repressing
certain downstream signaling molecules. Many in vivo studies demonstrate the
detrimental effects of excessive leukocyte cytokine signaling and show CXCR2 plays an
important role in inflammatory diseases, such as atherosclerosis [39], chronic
obstructive pulmonary disease [40], rheumatoid arthritis [41], multiple sclerosis [42],
oligodendrocyte derived neuroimmunological diseases [43, 44], inflammatory bowel
disease [45, 46], psoriatic epidermis [47], and in bronchial biopsies of chronic
obstructive pulmonary disease patients [48].

1.4 G-protein Signaling
CXCR2 is a seven-trans-membrane (7TM) spanning signaling receptor, which is
a distinct group of related proteins within the heterotrimeric G-protein coupled receptor
superfamily. G-proteins associate with the cytoplasmic side of 7TM receptors and
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mediate signal transduction by linking the receptor to one or many downstream effector
proteins [22, 49]. All GPCRs possess seven trans-membrane domains, having three
extracellular loops, and three cytosolic loops. The C-terminus is found in the cytosol
along with the 2nd and 3rd cytosolic loops, which are important for G-protein signaling
[50]. When stimulated by IL-8, CXCR2 initiates a series of G-protein mediated
downstream

events,

such

as

the

mobilization

of

intracellular

[Ca2+]

and

phosphatidylinositide hydrolysis, which generates inositol 1,4,5-trisphosphate (IP3) and
diacylglycerol (DAG), and initiates cellular responses [51].
CXCR2 interacts with a complex of heterotrimeric G-proteins, named Gα, Gβ,
and Gγ in order of decreasing mass. The α-subunits differ greatly from the other family
members, defining the nomenclature of individual complexes, and associate with DRY
motif (aspartate-arginine-tyrosine) on the 2nd cytosolic loop of CXCR2 [52]. Gβ and Gγ
tightly bind in a heterodimer (Gβγ), and associate with lipid membranes, where 7TM
receptors are imbedded [53]. In the resting state Gα binds GDP, forming GαGDP.
GαGDP associates with Gβγ, forming a GαGDP-Gβγ complex that contacts CXCR2
intracellularly, see Figure 1.1. Upon CXCR2 stimulation the GDP bound to Gα is
exchanged for GTP, resulting in a Gα subunit structural change, GαGTP then
dissociates from Gβγ and is free to diffuse from the membrane. Both dissociated
GαGTP and Gβγ are active forms of G-proteins and can modulate the function of
various downstream effectors. The GTP bound to Gα is hydrolyzed by an intrinsic
GTPase-function of Gα, forming GαGDP and inorganic phosphate. Once GTP is
hydrolyzed, GαGDP returns to the resting state by associating with Gβγ, completing the
signaling cycle [54] [55, 56].
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Figure 1.1 CXCR2 is a GPCR
CXCR2 is a seven transmembrane chemokine receptor. IL-8
CXCR2 inducing the associated Gα subunit to exchange GTP for
bound Gαβγ heterotrimer then dissociates into separate Gα
subunits, and activate downstream effectors. STTL refers to
carboxy-terminal PDZ motif (serine-threonine-threonine-leucine).

binds to
GDP. The
and Gβγ
CXCR2’s

GPCRs can function catalytically, amplifying the original signal, by activating
roughly 10 molecules of Gα over a few seconds [57, 58]. Furthermore, discriminatory
signaling by G-proteins produces a variety of low molecular weight second messengers,
including cyclic adenosine monophosphate (cAMP) or inositol triphosphate, further
amplifying the original signal. These small messengers selectively generate dramatic
intracellular changes, such as selective protein phosphorylation, gene transcription,
cytoskeleton reorganization and membrane depolarization [56]. There are multiple
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subtypes of each G-protein, although only certain combinations will form associable
heterotrimers. Gα subunits are divided into four different subtypes (Gαi, Gαs, Gαq and
Gα12/13) the Gβ subunit has five distinct subtypes (β1-β5), and Gγ subunits have ten
different subtypes, making up hundreds of combinations [59]. On top of all the possible
combinations of G-protein complexes that can associate with a single GPCR, multiple
receptors can activate a single effector, and a single receptor can activate multiple
effectors, forming complicated signaling networks [54, 60-63].
The time active Gα and Gβγ subunits remain separated for signaling is crucial,
and usually very short, depending entirely on how fast GTP is hydrolyzed by Gα. But the
intrinsic Gα GTPase-activity is usually long and insufficient, taking on the order of
minutes to complete. The GTPase-activity of Gα can be expedited by other proteins,
named GTPase-activating proteins (GAP). These GAPs can be the target protein of Gα
for downstream signaling, or a specific modulator known as a regulator of G-protein
signaling (RGS). For a review see [64]. In neutrophils, IL-8 stimulation of CXCR2 leads
to Gβγ activation of its downstream effector, phospholipase C β2 (PLCβ2), which
creates second messengers as well as stimulates calcium influx [25, 51, 65-67].

1.5 CXCR2 Contains a PDZ-motif
Regulation of CXCR2 signaling can be accomplished through receptor
desensitization, which uncouples G-proteins and internalizes the receptor, so the cell is
not as sensitive to ligand stimulation [68-71]. After chemokine stimulation G-proteincoupled receptor kinases (GRKs) phosphorylate CXCR2’s cytosolic tail and alter the
binding sites of CXCR2 modulators. The phosphorylation of CXCR2 is required for
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some processes, such as chemotaxis and internalization, but not others, like PLCβ2
activation and [Ca2+] mobilization [36, 72-75]. In neutrophils, IL-8 preferentially binds
CXCR2, inducing high levels of C-terminal tail phosphorylation and instigating rapid
CXCR2 internalization [76, 77].
CXCR2 sequestration is reliant on the endocytotic functions of clathrin-coated
pits and dynamin [78-80]. Receptor internalization is mediated by a peptide motif
recognized on the C-terminal tail of CXCR2, LLKIL (leucine-leucine-lysine-isolucineleucine), and an aspartate residue in the second extracellular loop [52, 81]. The LLKIL
motif is necessary for internalization by adaptin-2 (AP-2) [82]. After ligand stimulation,
phosphorylation of CXCR2’s C-terminus by GRK2 encourages binding of AP-2 as well
as βArrestin which form the clathrin coated vesicles necessary for internalization [83,
84]. Like other types of GPCRs, CXCR2 undergoes trafficking between intracellular
compartments and the membrane.
Once internalized CXCR2 has been de-phosphorylated it can be transferred to
late endosomes for degradation or recycled to the plasma membrane for another round
of signaling [77]. A domain was found in the C-terminus of CXCR2 that regulates postendocytotic sorting back to the cellular membrane [85]. Originally CXCR2 degradation
was thought to occur via the ubiquitination pathway, but is instead modulated by the
type I PDZ ligand on CXCR2’s C-terminus. CXCR2 lacking the PDZ ligand will be
shuttled to the late endosome, and degraded, at a much higher rate than the wild-type
(WT) CXCR2, ultimately affecting chemotaxis towards CXCR2 ligands [85].
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1.6 NHERF1 Binds CXCR2
The NHERF protein family consists of four members: NHERF1 (EBP50),
NHERF2 (E3KARP), NHERF3 (PDZK1) and NHERF4 (IKEPP). NHERF1 and NHER2
contain two PDZ domains while NHERF3 and NHERF4 possess four PDZ domains [86].
The human NHERF1 gene, SLC9A3R1, encodes a 358 amino acid protein (38.6kD)
with two tandem PDZ domains that share 74% homology [87]. High homology in PDZ
domains probably arose through evolutionary gene duplication as PDZ domains are
highly conserved modular structures which occur frequently throughout the genome and
are present in an overwhelming number of phyla [88-90].
The two NHERF1 PDZ domains, PDZ I and PDZ II, have similar secondary
structures, and collectively make up nearly 70% of NHERF1. They are followed by a 30
amino acid C-terminal region that associates with members of the merlin-ezrin-radixinmoesin family (MERM), a group of membrane-cytoskeleton adaptor proteins [91]. Both
PDZ domains of NHERF1 are type I PDZ domains, preferentially binding to short Cterminal peptide sequences of target proteins, X-(S/T)-X-(V/L) [92, 93]. NHERF1 binds
to cytoskeletal adaptor proteins through its MERM-binding domain, and links them to
integral membrane proteins through the PDZ motif on their C-terminal tail, such as the
one found in CXCR2 [94, 95]. Experiments show PDZ I and PDZ II domains bind to their
C-terminal PDZ-ligands at nanomolar affinity, to which crystal structures have
illuminated much of their specificity [96].
A crystal structure of NHERF1 binding to the C-terminal region of Cystic Fibrosis
Transmambrane Conductance Regulator (CFTR) was reported along with NHERF1
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binding to the β2 Adrenergic Receptor and Platelet-derived Growth Factor Receptor
(PDGFR) [96, 97]. These experiments demonstrate the NHERF1-PDZ I core domain
consists of six β strands (β1-β6) and two α helices (α1 and α2), and the PDZ-motif
inserts into the binding pocket in a β strand addition [98], see Figure 1.2. A slightly
larger hydrophobic binding pocket is found in NHERF1 compared to other type I PDZ
proteins, as NHERF1 prefers binding leucine at P0 instead of valine (P0 refers to the
ligands carboxy-terminal amino acid, the previous being P-1, P-2, etc.). Leucine was
shown to enter a deep cavity formed by Tyr24, Gly25, Phe26, Leu28, Val76, and Ile79
[2]. These residues form a tight hydrophobic pocket for the isobutyl side chain of P0
leucine and mediates the hydrogen bonding and coordination of H2O atoms, which
accounts for the strict stereochemical requirement of a C-terminal leucine [99-101].
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Figure 1.2 NHERF1 PDZ Domain-motif Interactions
The NHERF1 PDZ1 peptide-binding pocket (green) bound to the C-terminal PDZmotif (gray). Binding occurs in an antiparallel β strand addition, as the ligand fits
into a pocket between the α2 helix and the β2 strand. The PDZ-motif is a
consensus type I PDZ ligand, X-S/T-X-V/L (aspartic acid-glutamic acidglutamine-leucine). Water molecules are represented as green dots, hydrogen
bonds are orange dashed lines, and hydrophobic interactions are black dashed
lines. Image was obtained from [2].
A separate pocket for the P-2 side chain is also important for binding, as studies
showed NHERF1 preferentially binds to X-(S/T)-X-L, and changes resembling P-2
phosphorylation lost all PDZ domain-motif interaction [97, 99]. The P-2 amide nitrogen
and carbonyl oxygen both bind conserved residues in the PDZ domain binding pocket,
and the hydroxylated side chain oxygen atom of (S/T) at P -2 specifically interacts with
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the N3 nitrogen of a histidine residue in class I PDZ domains [2, 96]. The possibility of
7TM receptors C-terminus being phosphorylated, thus determining PDZ domain
interactions, has made a great impact in understanding regulatory functions of PDZcontaining GPCRs now that the specifics have been worked out. In vitro studies show
that phosphorylation of serine residues and binding of adaptor proteins to CXCR2’s Cterminus facilitate internalization and intracellular movement, which attests to the
importance of these C-terminal residues in CXCR2 cycling [102].
Another role of NHERF1 involves the regulation of small signaling molecules.
CXCR2 can stimulate activation of PLCβ2, which increases intracellular calcium levels
from [CA2+] stores, this in turn initiates an extracellular [CA2+] influx through storeoperated calcium channels (SOCs). It was shown that NHERF1 interacts with SOCs
and PLCβ2 through PDZ domains, suggesting NHERF1 can nucleate them into a
complex on the plasma membrane [103]. NHERF1 can also dimerize or oligomerize
through its two PDZ domains which could nucleate many receptors, ion channels,
effector molecules and actin-interacting proteins, using NHERF1 as a scaffold to stably
anchor these complexes to the actin cytoskeleton [104-106]. Recently we found
NHERF1 interacts with CXCR2 and PLCβ2 through PDZ-dependent interactions [1].

1.7 PLCβ2, CXCR2’s Downstream Effector
Mammalian phospholipase C-β2 (PLCβ2) is a multi-domain signaling enzyme
whose primary role is to generate low-molecular weight signaling molecules and
propagate signal transduction from 7TM receptors [107, 108]. During stimulation PLC
hydrolyzes the lipid phosphatidylinositol 4,5-bisphosphate (PIP2), generating two
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secondary messengers: inositol 1,4,5- trisphosphate (IP3), a potent calcium mobilizing
second messenger, and diacylglycerol (DAG), which activates the downstream effector
protein kinase C (PKC) [107], Figure 1.3. PLCβ2 is one of many Phosphatidylinositidespecific PLC enzymes which can ultimately be divided into six families: β γ δ ε ε, δ
and range between 85 to 150 kDa [109].

Figure 1.3 Activation of PLCβ2
PLCβ2 associates with the plasma membrane, as does Gβγ. Active Gβγ
stimulates PIP2 cleavage by PLCβ2, resulting in DAG and IP3 formation.
Downstream effects of DAG and IP3 formation include PKC activation and
calcium influx. ESRL corresponds to PLCβ2’s PDZ-motif (glutamic acid –
serine – arginine – leucine).
The β family consists of 4 isozymes, PLCβ1 through PLCβ4, which are regulated
by G-proteins and contain a consensus PDZ motif at their carboxyl termini (PLCβ2’s
PDZ-motif is glutamic acid – serine – arginine - leucine) [110]. PLCβ2 is primarily
expressed in hematopoietic cells, PLCβ3 and PLCβ1 are found in a wide variety of cells
and tissue types, and PLCβ4 is expressed predominantly in neuronal cells [111-113].
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Eukaryotic PLCβ enzymes contain a sequence of modular domains which are organized
around a catalytic α/β barrel formed from its conserved X and Y-box regions [114].
These modular domains include a pleckstrin homology (PH) domain, EF-hand motifs, a
C2 domain, and additional regulatory units present on the PLCβ and PLCγ subtypes
[107].
The PH domain is a highly conserved motif around 120 amino acids in length that
confers specificity to different lipids or proteins and is located in the N-terminal region of
PLC [115]. PH domains are prominently found in proteins associated with cellular
membranes and can bind specific phosphoinositides (e.g. PIP2, PIP3), although
PLCβ2’s PH domain is not phosphoinositide specific [116-119]. They also have the
ability to bind Gβγ subunits especially in PLCβ2 where Gβγ binding to the PH domain
is sufficient for enzymatic activation, and increases product release [119-121].
Furthermore, CXCR2 activity is able to recruit a variety of proteins through inositidespecific PH domains to the leading edge of migrating cells [122].
Regulation

of

Gβγ

subunit

specific

activation

of

PLCβ2

is

through

phosphorylation by cAMP-dependent protein kinase A (PKA) [123]. In response to
CXCR2-PLCβ2 mediated calcium influx, some forms of adenylyl cyclase will activate a
downstream protein kinase, thereby phosphorylating and deactivating PLCβ2,
repressing calcium influx [124]. Phosphorylation by PKA also uncouples receptors that
signal through Gαi proteins, such as CXCR2 which alludes to a greater on-off switch of
PLCβ signaling [125].
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1.8 Chemokine Signaling Triggers Chemotaxis
When the neutrophil cell surface receptor CXCR2 is stimulated from the
inflammatory chemokine IL-8, the G-protein heterotrimer becomes activated. CXCR2
coupled G-protein signaling triggers a variety of downstream effects which ultimately
dictate cellular behavior and spur the cell to polarize its cytoskeleton, form actin derived
pseudopodia, and begin chemotaxis [126-128]. The asymmetric manner in which cells
polarize involve a slew of feedback mechanisms that modulate actin extension at the
leading edge (frontness pathway) and promote contractile cytoskeletal forces at the rear
(backness pathway) [129, 130]. The first level of response in chemotaxing cells is the
separation of uniformly distributed transmembrane chemoattractant receptors into the
asymmetric localization of phosphatidylinositol 3,4,5-trisphosphate (PIP3) [131].
Proteins that interact with, synthesize, or degrade PIP3 are the first effectors in the
signaling process and they utilize PIP2, the same precursor molecule used by PLCβ2.
When PLCβ2 cleaves PIP2, IP3 and DAG are formed, and PIP2 is enzymatically
removed from that region of local membrane. IP3 dissociates from the membrane and
binds to its receptor on the surface of the endoplasmic reticulum (ER) which stimulates
an increase of intracellular [Ca2+]. The spike in intracellular [Ca2+] initiates an influx of
extracellular [Ca2+] through SOCs to replenish the depleted internal stores, and also
activates [Ca2+] dependent enzymes. DAG, the cleaved lipid portion of PIP2, in
conjunction with an influx of [Ca2+] from IP3, activates Protein Kinase C (PKC) which
helps propagate the original signal by phosphorylating target proteins. A few different
isoforms of PKC are expressed in human neutrophils, and PKC activity is crucial for
neutrophil chemotaxis, but not actin mobilization [132-135].
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Instead of cleaving the inositol head-group off the glycerol-lipid side chains, like
PLCβ2, some proteins phosphorylate or de-phosphorylate the head-group. One of these
proteins is the class I phosphatidylinositol-3-kinase γ enzyme (PI3K), which is
expressed mainly in hematopoietic cells [136]. PI3K phosphorylates the 3’ position on
inositol phospholipids in the cytosolic plasma membrane, namely PIP2 (phosphorylated
on inositol carbons 4 and 5) is converted to PIP3 (phosphorylated on inositol carbons 3,
4 and 5) [137]. PI3K is stimulated by free Gβγ subunits from activated CXCR2, or
another small G-protein Rac-1, which are both localized to the leading edge of polarized
neutrophils [138-140].
As PI3K is localized to portions of the plasma membrane, other proteins such as
PTEN (phosphatase and tensin homology deleted on chromosome ten protein), are
delocalized from the front of the cell and become restricted to the rear and lateral sides.
PTEN is a phosphatase that removes the 3-position phosphate from the inositol ring,
thereby converting PIP3 back into PIP2 [122, 141, 142]. Re-localization of PTEN occurs
through a PIP2 binding domain on its N-terminus, which associates with areas of PIP2
accumulation [143]. PTEN also contains a PDZ-motif and forms a ternary complex with
NHERF2, PTEN and PDGFR, which has been implicated in chemotaxis and tumor
growth [144].
Like PTEN, SHIP-1 co-localizes with PIP2 and is responsible for removing the 5position phosphate from inositol rings in human neutrophils [145]. Thus, CXCR2
downstream effectors will remove PIP2 from the leading edge, thereby removing
PTEN/SHIP-1 from the leading edge leaving PI3K to phosphorylate PIP2 into PIP3
[146-148]. A reciprocal accumulation of PIP3 is formed at the leading edge and a
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surplus of PIP2 is dispersed throughout the cells lateral and posterior areas essentially
forming a phosphatidylinositol gradient, which reflects the extracellular chemokine
signal [149].
Evidence suggests that localization of PIP3 results in the polymerization of Factin at the leading edge, which leads to pseudopod formation and extension by the
Rho-family-GTPases Rac-1 and Cdc42 [150-154]. In vitro studies have linked PIP3
activity with Rac-1 and Cdc42, which are protein moderators involved in actin dynamics
and possesses GTPase activity (active only when bound to GTP) [155, 156]. A
disruption of a Rac-1 GAP, DdRacGAP1, leads to increased levels of actin
polymerization and pseudopod formation, and a dominant negative form of Rac-1
prevents pseudopod formation and cell migration [157]. PRex-1 exchanges GDP for
GTP on Rac-1 and is synergistically activated by the PI3K product PIP3 and active Gβγ
subunits, suggesting GPCR stimulation and subsequent PI3K activity is sufficient for
Rac-1 to be activated [154, 158, 159]. Active Rac-1 is necessary for pseudopod
formation and actin mobilization at the leading edge and together with active Gβγ can
stimulate PI3K activity. This facilitates a feedback loop by creating more PIP3, activating
PRex-1, which promotes Rac-1 activity [160, 161].
In a similar fashion to Rac-1, Cdc42 is important for cellular chemotaxis and
cellular polarity. A dominant negative expression of Cdc42 causes cells to move
randomly in chemokine gradients and disrupts polarization [162-165]. Gβγ subunits
cause Cdc42 to activate PAK1, a serine/threonine protein kinase [166]. PIXα, a small
GEF that contains a PH domain, is constitutively associated with PAK1, and mediates
the activation of Cdc42 by Gβγ in vivo [167-169]. PIXα activity is also required for PTEN
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localization to the trailing edge of cells, probably through activation of Cdc42 [167]. This
suggests Cdc42 is required for intracellular gradient formation of a chemoattractant
signal and Rac-1 is required to promote movement by stimulating actin mobilization.
The induction of leading edge actin polymerization is mediated by the Arp2/3
protein complex. A huge variety of GEFs can promote Rac-1/Cdc42 activation, and
downstream effectors of Rac-1 and Cdc42, such as WAVE (SCAR) and WASP
(Wiskott-Aldrich Syndrome protein) promote Arp2/3 actin polymerization [170, 171].
SCAR and WASP contain actin binding domains, selective phospholipid binding
domains similar to PH domains, and both are activated by PIP3 [172, 173].
Furthermore, they only interact with the activated (GTP-bound) forms of Rac-1 and
Cdc4, thus localizing actin, active Cdc42/Rac-1, PAK1 and the ARP2/3 complex
together near sites of PIP3 accumulation and Gβγ subunits [174].

1.9 CXCR2 Modulators
LASP-1 is a cytoskeletal scaffold protein implicated in actin bundling and
stabilization, and binds to CXCR2 in both basal and activated forms on the LLKIL motif
necessary for AP-2 sequestration [175-177]. Furthermore, LASP-1’s SH3 domain
interacts with proteins that localize to the leading edge of migratory cells and plays an
important role in cytoskeletal organization and migration in neutrophil like HL-60 cells
[178, 179]. Another CXCR2 binding protein, Vasodilator-stimulated phosphoprotein
(VASP), promotes actin filament elongation and pseudopod formation by regulating
actin networks, attracting profiling-actin complexes, and destabilizing actin-capping
proteins [180-184]. Both VASP and LASP-1 can be controlled by regulatory kinases
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PKA and PKG. VASP can also be phosphorylated by PKC, which contributes to their
regulation once IL-8 signaling is initiated [185-188].
IQGAP1 is postulated to bind CXCR2 in its inactive form and, once Cdc42 is
activated, IQGAP1 will associate with activated Cdc42, enabling IQGAP1 to release
CXCR2. IQGAP1 then is free to dimerize and bind F-actin, cross-link actin filaments,
and mediate chemotaxis [38]. Furthermore, IQGAP1 binds and inhibits the GTPase
activity of Cdc42/Rac-1, stabilizing them in active-signaling forms [189, 190]. Two other
proteins that affect GTPase activity of CXCR2’s G-proteins are 14-3-3γ and RGS12. 143-3γ inhibits RGS proteins, allowing Gα subunits to remain active for a longer period of
time [191, 192]. The GAP protein RGS12 associates with CXCR2 through its PDZ
domain, and stimulates Gα to hydrolyze GTP and return to its resting state. The
interplay between RGS12, 14-3-3γ and CXCR2 is thought to control CXCR2 G-protein
signaling after IL8 initiation, but their regulation is still unknown [64, 193, 194].

1.10 Formation of the Uropod
Uropod contraction (backness pathway) at the rear of the cell is necessary to
allow the cell to move forward towards the leading edge. In neutrophils backness
signals, which include PTEN/SHIP-1 localization, activation of a second GTPase (Rho),
a Rho-dependent kinase (p160-ROCK), and Myosin II activation, results in actomyosin
contraction at the rear of the cell [195-198]. Activated GTPase Rho is responsible for
activation of p160-ROCK, which enhances phosphorylation of myosin light chain (MLC),
inhibits MLC phosphatase, and stimulates actin-myosin contraction [199]. MLC
contraction is also dependent on [Ca2+] /Calmodulin for proper function, as a PLCβ2
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mediated [Ca2+] influx is required for proper tail retraction and detachment from certain
substrates [200].
Despite a requirement for migrational frontness, Cdc42 also plays an essential
role in Rho activation in the uropod [169, 201, 202]. These small G-proteins act as
another layer of signaling on top of the PIP2/PIP3 separation in cells, as Rho inhibits
Rac-1 frontness activity, actin assembly, polarity, and motility, and active Rac-1
represses Rho activity in the uropod [195, 203]. This all implies a Rac-1 dependent
frontness and a Rho-dependent backness that regulate cellular polarity, initiated
through CXCR2/G-protein activation of Cdc42.

1.11 A Means to an End
Neutrophils respond to stimulating signals in a hierarchical manner. “End target”
signals, such as bacterial products like N-formyl-methionine-leucine-phenylalanine
(fMLP), are preferred targets over “intermediate” signals, such as chemokines like IL-8
[204]. fMLP is a potent chemoattractant and has been implicated in directing cell
movement, phagocytosis, release of proteolytic enzymes, cytokine production and
generation of reactive oxygen intermediates [205]. The human formyl-peptide receptor
(FPR), belongs to the seven transmembrane GPCR superfamily, like CXCR2, and is
expressed on neutrophils as well as many other inflammatory cells. Since bacteria and
mitochondria are the only two sources of formylated peptides, FPR can direct
inflammatory cells to sites of either bacterial invasion or host tissue damage [206].
Neutrophils can distinguish between the intermediary and end target signals
through their different intracellular signaling pathways. Proof of this was established as
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treatment of neutrophils with PI3K inhibitors represses IL-8 migration, but not fMLP
migration. Even though both IL-8 and fMLP can activate the same isoform of PI3K and
mediate responses in a PIP3 dependent manner, fMLP, but not IL-8, activates p38
mitogen activated protein kinase (MAPK) [207, 208]. fMLP signaling also activates a
different phospholipase than IL-8, phospholipase A2 (PLA2), which converts
phosphatidylcholine to arachidonic acid, and along with MAPK activity permits the cells
to further respond to bacterial products [209]. What is more interesting it that PI3K
activity is abolished when both intermediate and end target signals are present, so that
intermediary signals are disregarded. This is thought to occur through a MAPKdependent activation and/or re-localization of PTEN to the plasma membrane, which
reverts PIP3 back into PIP2.

1.12 Summary of IL-8 Migration
In summary, localized areas of inflammation will produce chemokines to attract
immune cells to repair damage. The highly potent IL-8 is received by CXCR2 on
neutrophil membranes and spurs chemotaxis towards the signal. IL-8 stimulated
CXCR2 will activate Gα and subsequently free Gβγ, which in turn activates local PLCβ2
and PI3K. PLCβ2 converts PIP2 into IP3 and DAG, which act synergistically to begin a
signaling cascade through PKC and calcium affected proteins. PI3K phosphorylates
PIP2 creating PIP3, and together with PLCβ2 remove PIP2 from the area of CXCR2/IL8 stimulation, forming a PIP3 gradient near active CXCR2. PTEN/SHIP-1 colocalizes
with PIP2 and is sequestered to the posterior and lateral sides of the cell. The re-
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localization away from the front of the cell allows all PIP3 that diffuses away from the
leading edge to be converted back to PIP2, isolating the PIP3 to the leading edge.
At the leading edge PIP3 and Gβγ synergistically promote GTP exchange of
Rac-1. Active Rac-1 recruits WASP and SCAR through its CRIB domain, which both
increase Arp2/3 complex-mediated actin polymerization. Rac-1 also stimulates PI3K
activity increasing PIP3 formation, creating a positive feedback loop that is localized at
the leading edge of the cell. Cdc42 is also activated by Gβγ and PI3K action on the GEF
PIXα. These active proteins are recruited to sites of PIP3 and actin polymerization by
Arp2/3 effectors similar to Rac-1, where they stimulate actin-derived pseudopod
formation and create a leading edge. Furthermore active Cdc42 triggers Rho activity,
and through p160-ROCK, Myosin II, and PLCβ2-derived calcium influxes, actomyosin
fibers begin to contract in the uropod [210]. Thus, sites of CXCR2 stimulation ultimately
lead to areas of actin polymerization and forward movement. See Figure 1.4.
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Figure 1.4 PIP3 Dictates Cellular Polarization
After ligand binding to CXCR2 a local population of PIP3 is produced,
forming an intracellular gradient. PIP2 is removed from the leading edge
through PLC2 and PI3K, and accumulates in the posterior. PIP3 recruits
proteins involved in migrational frontness including Cdc42, Rac-1, the
Arp2/3 complex, and actin modulating proteins.
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CHAPTER 2
MATERIALS & METHODS
2.1 Antibodies and Reagents
Anti-human and murine CXCR2, PLCβ1, β2, and β3 antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-NHERF1 polyclonal
antibody was from Sigma, and mouse anti-NHERF1 monoclonal antibody was from
Santa Cruz. Anti-HA HRP and anti-FLAG HRP were obtained from Sigma.
Lipofectamine 2000, Hanks' buffered salt solution (HBSS), Fura-2, and the cell culture
media and fetal bovine serum (FBS) were procured from Invitrogen. ChariotTM
peptide/protein delivery reagent was purchased from Active Motif (Carlsbad, CA).
Chemokines IL-8/CXCL8, growth-related oncogene α (GROα/CXCL1) and N-formylmethionine-leucine-phenylalanine (fMLP) were obtained from ProSpec (East Brunswick,
NJ). The human and murine CXCR2 C-tail peptides (biotin-conjugate at N terminus):
WT (biotin-FVGSSSGHTSTTL for human CXCR2 C-tail; and Biotin-FVSSSSANTSTTL
for mouse CXCR2 C-tail) PDZ motif deletion ΔTTL, or PDZ motif mutant, AAA, were
synthesized by Genemed Synthesis, Inc. (San Antonio, TX).

2.2 Plasmids, Cloning, and Mutagenesis
The His-S-tagged fusion proteins for the full-length of CXCR2 or PLCβ2, or the
C-terminal tail fragments of CXCR2 (last 45 amino acids; i.e. amino acids 316–360 for
human CXCR2, and amino acids 315–359 for murine CXCR2) or human PLCβ2 (last
100 amino acids, i.e. amino acids 1086–1185) were generated by PCR cloning into
pTriEx-4 or pET30 vectors (Novagen). The fusion proteins were purified using Talon
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beads (binding to His tag), and eluted with 200 mm imidazole. The imidazole-eluted
affinity-purified His-S-tagged CXCR2 or PLCβ2 fusion proteins (full-length and/or Cterminal tail fragments) were used in subsequent biochemical assays.

2.3 Cell Culture and Transfection
The HL-60 cells were obtained from American Type Culture Collection (ATCC)
(Manassas, VA) and maintained in Iscove's modified Dulbecco's medium (Invitrogen)
supplemented with 10% FBS, and penicillin/streptomycin at 37 ºC with 5% CO 2. HL-60
cells were differentiated into the granulocyte lineage with 1.2% Me 2SO in Iscove's
modified Dulbecco's medium with 10% FBS for 5–7 days. The HEK293 cells and HT-29
human colonic epithelial cells were purchased from ATCC and cultured in Dulbecco's
modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% FBS as
described before [211]. HEK293 cells were transfected using Lipofectamine 2000 with
HA-tagged human CXCR2, murine CXCR2, and FLAG-tagged PLCβ1, β2, β3, and β4,
respectively, for various biochemical assays.

2.4 Human Neutrophil Isolation from Buffy Coats
Briefly, neutrophils from buffy coats (purchased from LifeBlood Inc.) of citrated
human peripheral blood collected from healthy donors were isolated by dextran
sedimentation followed by density gradient centrifugation in Histopaque (Sigma), as
described in [212]. Contaminating red blood cells were lysed by hypotonic shock with
0.2% NaCl. The purity and viability of isolated neutrophils was assessed by trypan blue
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dye exclusion, and the viability of isolated neutrophils was routinely found to be >98%.
Neutrophils were used immediately after isolation for all assays.

2.5 Murine Neutrophil Isolation from Mouse Bone Marrow
Isolation of murine neutrophils from bone marrow was carried out as reported
previously [213]. Briefly, the femurs and tibias were removed from euthanized mice and
the bone marrow cells were flushed out of the bones with ice-cold Ca2+- and Mg2+-free
HBSS (HBSS−). Bone marrow cells were collected by centrifugation at 800 × g for 5
min, and then resuspended in 3 ml of HBSS −. The cells were layered over a
discontinuous 3-layer Percoll (Amersham Biosciences) gradient (75, 67, and 52%) and
subjected to centrifugation at 1,060 × g for 30 min at 22–24 ºC. The lowest band
between 75 and 67% (the 75/67% interface) was then collected as the neutrophil
fraction and washed twice with HBSS−. Any remaining red blood cells were eliminated
by hypotonic lysis, and the purity of the neutrophils was typically ≥90% as assessed by
crystal violet staining.

2.6 Western Blots
Cells were washed twice in PBS, then lysed in lysis buffer (PBS, 0.2% Triton)
supplemented with protease inhibitors (1 mm phenylmethylsulfonyl fluoride 1 μg/ml of
aprotinin 1 μg/ml of leupeptin and 1 μg/ml of pepstatin) and HALT phosphatase
inhibitor cocktail (Thermo Scientific), and the clear supernatant (16,000 × g, 15 min) was
assayed for protein concentration using Quick Start Bradford Dye Reagent (BIO RAD).
Samples were mixed with NuPAGE LDS Sample Buffer 4x (Invitrogen) containing 10%
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2-mercaptoethanol (BIO RAD) and heated to 70ºC for 10min and separated by SDSPAGE on Mini-PROTEAN precast TGX-Gels (BIO RAD) 7.5%, any-KD, or Express
PAGE gels 10% (GeneScript). The membranes were immunobloted with NHERF1,
NHERF2, or PLCβ1 β2 β3 antibodies and visualized using a BioSpectrum 500 Imaging
system (UVP).
2.7 Pulldown Assay
Freshly isolated human or murine neutrophils, dHL60 cells, or HEK293 cells
overexpressing various constructs (3HA-tagged human CXCR2, murine CXCR2, or
FLAG-tagged PLCβ1, β2, β3, β4) were used for the GST pulldown assays, as reported
in [211, 214]. In brief, the cells were lysed in lysis buffer (PBS, 0.2% Triton)
supplemented

with

a

mixture

of

protease

inhibitors

(containing

1

mm

phenylmethylsulfonyl fluoride 1 μg/ml of aprotinin 1 μg/ml of leupeptin and 1 μg/ml of
pepstatin) and phosphatase inhibitor mixture (Sigma), and the clear supernatant
(16,000 × g, 15 min) was mixed with various GST-PDZ fusion proteins (GST-NHERF1,
GST-NHERF2, or GST-PDZK1) or GST alone at 4 ºC for 3 h. The complex was pulled
down by glutathione-agarose beads (BD Biosciences) at 4 ºC for 1 h, washed three
times with lysis buffer

and eluted in Laemmli sample buffer containing β-

mercaptoethanol. The eluents were separated by SDS-PAGE and immunoblotted with
anti-HA, CXCR2, or PLCβ1, β2, β3, or anti-FLAG (for PLCβ4) antibodies, and the blots
were visualized using a BioSpectrum 500 Imaging system (UVP).
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2.8 Pairwise Binding
Purified GST-NHERF1 was mixed with purified His-S-CXCR2 C-tail fragments in
binding buffer (PBS, 0.2% Triton) supplemented with a mixture of protease inhibitors at
22–24 ºC for 1 h. Next the mixtures were incubated with S-agarose beads (Novagen) for
2 h. The beads were washed three times with binding buffer and eluted with Laemmli
sample buffer. The eluents were separated by SDS-PAGE and immunoblotted with antiNHERF1 antibody.

2.9 Macromolecular Complex Assembly
Purified His-S-tagged PLCβ2 C-tail (last 100 amino acids at C terminus
containing the PDZ motif) or His-S-murine CXCR2 C-tail (last 45 amino acids at the Cterminus containing the PDZ motif) was mixed with GST-PDZ scaffold proteins (or GST
alone) in 200 μl of binding buffer (PBS 0.2% Triton, supplemented with protease
inhibitors), and the complex was pulled down with S-protein-agarose. This step is also
referred to as pairwise binding as described above. The dimeric complex was then
mixed with HEK293 cell lysates overexpressing 3HA-CXCR2 or full-length PLCβ2 for 3
h at 4 ºC, and washed extensively with lysis buffer. The bound proteins were then eluted
and immunoblotted using anti-HA (for CXCR2) or PLCβ2 antibodies.

2.10 Co-immunoprecipitation
Fresh cells (dHL-60 or murine bone marrow neutrophils) were cross-linked with 1
mm dithiobis (succinimidyl propionate), [215].Thereafter, the cells were solubilized in
PBS, 0.2% Triton, and cleared lysates (16,000 × g, 15 min) were processed for co-
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immunoprecipitation and immunoblotting, as described before [211, 214]. A Coimmunoprecipitation Kit (Pierce) was used to immobilize the anti-CXCR2 IgG to the
resin and the co-precipitated protein complex was eluted with Laemmli sample buffer
before being subjected to immunoblotting and probed for PLCβ2 and NHERF1. The
same membrane was stripped using RestoreTM Plus Western blot Stripping Buffer
(Thermo Scientific) and reprobed for CXCR2.

2.11 CXCR2 Peptide in Vitro Competitive Binding
In brief, affinity-purified HA-tagged human CXCR2 (37.5, 75, and 150ng) was
immobilized on the nitrocellulose membrane by spotting, and the membrane was
blocked with TBS, 0.1% Tween supplemented with 1μg/ml of BSA (TBST-BSA) for 1 h
at 22 ºC. During this time, 10μg of His-S-tagged NHERF1 was mixed with TBST-BSA in
the presence or absence of 25μg of human CXCR2 C-tail WT peptide for 1 h at 22–24
ºC, and then the mixture was added to the membrane and incubated for 12 h at 4 ºC.
The membrane was washed extensively and immunoblotted with S-HRP (Novagen),
which detects the S-tag within the His-S-NHERF1 fusion proteins on Western blot.

2.12 CXCR2 Degradation
HL-60 cells were differentiated into the granulocyte lineage (dHL-60) as
previously described. 1x10^6 cells dHL-60 cells were delivered 3.33ug of peptide (WT
or DEL) through the ChariotTM peptide/protein delivery system, per the Chariot protocol
(www.activemotif.com/documents/5.pdf) [214]. Cells were incubated for 0min, 3hours,
or 6hours, in IMDM supplemented with 0.5% FBS and IL-8 (100ng/ml). Samples were
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then rinsed, pelleted, and lysed in lysis buffer as described above. Protein estimations
were taken and a Western blot was performed on the samples to determine total
CXCR2 amount [80]. Processing of the Western blot data was completed as described
previously.

2.13 Zigmond Migration Chamber
HL-60 cells were differentiated into the granulocyte lineage (dHL-60), with 1.2%
DMSO in IMDM medium with 10% FBS for 5-7 days as described above [83, 216].
CXCR2 C-tail peptide (0.333ug of

T or ΔTTL) was delivered to 3x105 dhL60 cells

through the ChariotTM peptide/protein delivery system [214]. 22x40-1.5 mm glass cover
slips (Fisher Scientific) were coated in fibronectin, and dHL-60 cells were allowed to
adhere to the slips for 30min. Cells were rinsed in IMDM and the coverslip was inverted
onto the top of the Zigmond chamber. Clamps were applied to secure the coverslip in
place and 90ul of IMDM was added to each chamber well [217, 218]. See Figure 2.1.
The Zigmond chamber was placed in a TC1-100 microscopic temperature
controller (37ºC, Bioscience Tools), and mounted onto a VWR (Randor, PA) microscope
with a Vista Vision mounted camera. Chemoattractants, 50ng/ml IL-8 or 0.5uM fMLP,
were added to the appropriate wells [83]. Images were captured on uIMAGE micro
image analysis software, every 30 seconds for a total of two hours (240 images) [219].
The images were processed using ImageJ software (http://rsbweb.nih.gov/ij/), migratory
paths

were

tracked

using

the

Manual

Tracking

plug-in

(http://rsbweb.nih.gov/ij/plugins/track/track.html), and any additional data processing
was obtained using the Chemotaxis Tool (http://www.ibidi.com/) and through Microsoft
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Excel. dHL-60 cells that migrated were randomly selected for tracking from each
experiment.
2.14 Statistical Analysis
Error is expressed as the standard deviation of at least three independent
experiments. Statistical significance of the migration experimental data was determined
by the Rayleigh test, a value of p < 0.05 is considered to be significant.

Figure 2.1 Zigmond Chamber
An illustration of the Zigmond chemotaxis chamber, the only difference
between the wells (colored pink and orange) is the presence of a
chemokine, which will diffuse through the gap created between the
chamber bridge and a glass coverslip. As chemokine diffuses across the
gap a gradient is formed (see curved arrow). Chemotaxing cells will
respond to the gradient and migrate along the fibronectin coated coverslip
towards the well containing IL-8.
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CHAPTER 3
RESULTS
3.1 HL-60 Differentiation
Due to differences in expression of components used for receptor signal
transduction, it was important to choose a cell line which closely resembles naturally
occurring human neutrophils. It is beneficial to study CXCR2 in cells that naturally
express

the

receptor

and

its

complementary

components,

opposed

to

an

overexpression system which can take the signaling mechanism out of context. HL-60
cells differentiated along the granualocytic pathway closely resemble neutrophils in
many facets and, most importantly, express endogenous CXCR2 [220]. These cells are
hematopoietic in origin, derived from a patient with acute promyelocytic leukemia, and
represent a pluripotent lukemic cell line used extensively in laboratory research [221].
HL-60 cells are an immense contribution to the study of leukocytes and represent a
reliable cell line for inflammatory research [222].
The HL-60 promyelocytes can be differentiated towards neutrophils (the
granulocyte lineage) with exposure to Me2SO (DMSO) [220]. Once HL-60 cells begin
differentiation there is an increased expression of various chemokine receptors and
their G-protein regulators, equating them towards naturally produced neutrophils [223226]. These differentiated cells have been used extensively to study G-protein signaling
and various other neutrophilic and monocytic activities. Differentiated HL-60 cells
polarize,

migrate

towards

chemoattractants,

and

detect

chemokine

comparable to human neutrophils isolated from peripheral blood [13, 151].

gradients
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3.2 Human Neutrophils and dHL-60 Cells
The NHERF proteins, like many other PDZ proteins, play a role in organization of
plasma membrane domains, through clustering and anchoring specifically recognized
motifs of target proteins [90]. PDZ mediated binding of NHERF1 is important at both
ends of chemotaxing cells and provides multiple points of interaction for PDZ-motif
containing proteins. CXCR2 possesses a PDZ-motif, suggesting CXCR2 becomes
anchored to the scaffolding protein similar to SOCs PLCβ2 or PTEN and PDGFR
[227].
Like CXCR2 the PLCβ family contains a type I PDZ-motif at their carboxy
terminus. The small signaling molecule generators PLCβ1 PLCβ2 and PLCβ3 were
investigated to determine their expression in dHL-60 cells. PLCβ2 and PLCβ3 are
important in HL-60 differentiation along the granulocytic pathway, as their nuclear
localization coincides with differentiation [228]. PLCβ2 is the prominent isoform
expressed in human neutrophils, and is by and large the major isoform functioning
during neutrophil chemotaxis, bearing responsibility for IP3 production and [Ca2+] influx,
while PLCβ3 plays only a small role and PLCβ1 is non-existent [229-231]. If dHL-60
cells express proteins similar to human neutrophils, the data would be more relevant in
in vivo models of human inflammation.
I used a Western blot to assay expression of proteins in dHL-60 cells, Figure 3.1.
The data shows dHL-60 cells express NHERF1 (A), however NHERF2 (B) is
undetectable in dHL-60 cells and seems to have a very low level of expression in
undifferentiated HL-60 cells. PLCβ1 (C) was undetected in dHL-60 cells, which is
congruent with other findings, and coincides with expression in neutrophils, which only
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express PLCβ2 and PLCβ3 [232]. Differentiated HL-60 cells express high levels of
PLCβ2 (D) and low levels of PLCβ3 (E) which also coincide with human neutrophils. As
expected, dHL-60 cells produce proteins necessary for chemokine signal transduction,
similar to other leukocytes.

Figure 3.1 dHL-60 Expression of NHERF and PLC Isoforms
All dHL-60 samples contain 30ug of protein lysate, each membrane is
immunobloted with the appropriate antibody. (A) NHERF1 expression is
detected and the purified His-S-tagged NHERF1 (N1) protein is used as a
control. (B) NHERF2 expression is undetected compared to various cancer
and HL-60 samples, known to express NHERF2, (His-S-tagged NHERF2 was
undetectable). (C) PLCβ1 expression, undetected, compared to HEK cells
overexpressing PLCΒ1. (D) PLCβ2 expression in dHL-60 cells compared to
HEK cells overexpressing PLCβ2, expression is consistent with
expectations. (E) PLCβ3 expressed at low levels, compared to control
sample cells known to express PLCβ3.
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3.3 Biochemical Assay Results
Due to PDZ-motif presence on CXCR2, initial studies linking CXCR2 and the
NHERF proteins were carried out, [1] refers to our published article. Through a GSTtagged pulldown assay we found human CXCR2 overexpressed in HEK293 cells binds
the scaffolding proteins NHERF1, NHERF2 and slightly to PDZK1 (NHERF3), see
Figure 3.2 (A). Murine CXCR2 from HEK overexpression (B) and, isolated from bone
marrow neutrophils can also be pulled down by NHERF1, but not NHERF2 or NHERF3
(D). Furthermore, CXCR2 derived from human neutrophil cells preferentially interact
with NHERF1, and can also bind NHERF2 (C), and this is also observed in CXCR2 from
dHL-60 cells (E).
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Figure 3.2 CXCR2 Interacts with NHERF
CXCR2 preferentially interacts with NHERF1 in neutrophils. (A), HA-tagged human
CXCR2 (overexpressed in HEK293 cells) was pulled down by PDZ scaffold proteins
(NHERF1, NHERF2, and PDZK1). The membrane was blotted with anti-HA
monoclonal antibody. (B), His-S-tagged murine CXCR2 (overexpressed in HEK293
cells) was pulled down by the indicated PDZ scaffold proteins. The membrane was
blotted with anti-mouse CXCR2 monoclonal antibody. (C), NHERF1 and NHERF2
bound to endogenous CXCR2 from human neutrophils. The membrane was
immunoblotted with anti-human CXCR2 monoclonal antibody. (D), NHERF1 bound
to endogenous CXCR2 from murine bone marrow neutrophils. Cell lysates of
HEK293 cells that overexpressed 3HA-murine CXCR2 were loaded as a positive
control. The membrane was immunoblotted with anti-murine CXCR2 monoclonal
antibody. (E), NHERF1 and NHERF2 bound to endogenous CXCR2 from neutrophillike cells, dHL-60 cells. The membrane was immunoblotted with anti-human CXCR2
monoclonal antibody. Taken from [1].
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e performed a similar experiment on PLCβ isoforms, Figure 3.3, as they also
possess C-terminal PDZ-motifs. The direct downstream effector of CXCR2 G-protein
signaling PLCβ2 (B) along with PLCβ1 (A) and PLCβ3 (C) preferentially bind to
NHERF1 and somewhat with NHERF2. This is shown through a GST-tagged pulldown
of HEK293 cells overexpressing each PLCβ isoform. Further, data showed PLCβ2 from
murine bone marrow neutrophils (D) and dHL-60 cells (E) preferentially interact with
NHERF1. Bearing in mind leukocytes have high levels of PLCβ2 and NHERF1, the
scaffolding protein NHERF1 was considered to naturally bind both CXCR2 and PLCβ2
in leukocytes.
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Figure 3.3 PLCβ Isoforms Interact with NHERF
PLC-β isoforms physically interact with PDZ scaffold proteins, whereas PLC-β2
in neutrophils preferentially interacts with NHERF1. A–C, HEK293 cells were
overexpressed with FLAG-tagged PLC-β1 (A), PLC-β2 (B), and PLC-β3 (C), and
the GST pulldown assays were performed with PDZ scaffold proteins as
described under “Experimental Procedures.” The membranes were
immunoblotted with anti-PLC-β1 (A), PLC-β2 (B), and PLC-β3 (C) monoclonal
antibodies, respectively. Purified His-S-PLC-β1 (20ng) was loaded as positive
control for the PLC-β1 antibody (A). D and E, endogenous PLC-β2 from
neutrophils freshly isolated from mouse bone marrow (D), or from neutrophillike cells, dHL-60 cells (E), was pulled down by PDZ scaffold proteins. The
membranes were immunoblotted with anti-PLC-β2 monoclonal antibody.
Purified His-S-PLC-β2 was loaded as positive control for the PLC-β2 antibody.
Image obtained from [1].
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We hypothesized the PDZ scaffold proteins, namely NHERF1, would complex
CXCR2 and PLCβ2 in a PDZ motif-dependent manner, and we were successfully able
to assemble a complex of CXCR2, PDZ scaffold proteins, and PLCβ2 in vitro, Figure
3.4. His-S-C-tail derivatives of either CXCR2 or PLCβ2 were pulled down by S-protein
agarose beads. The complement purified protein (PLCβ2 or CXCR2, respectively) was
probed for by Western blot. The pulldown of either His-S-CXCR2 C-tail or His-S-PLCβ2
C-tail can precipitate the entire complex, and NHERF1 seems to be the favored
scaffolding protein, and is necessary for complex formation. We also observed complex
formation from murine bone marrow neutrophils endogenous CXCR2 and PLCβ2
mediated by NHERF1 in vivo. Furthermore we found NHERF1-CXCR2 binding to be
dose-dependent.
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Figure 3.4 Macromolecular Complex Formation
CXCR2, NHERF1, and PLC-β2 form a macromolecular complex in vitro and in
neutrophils. (A), schematic representation of in vitro macromolecular
complex assembly (upper panel, refer to “Materials & Methods” for details).
Macromolecular complex of PLC-β2 C-tail, PDZ scaffold proteins, and human
full-length CXCR2 (lower panel) are shown. (B), macromolecular complex of
PLC-β2 full-length, PDZ scaffold proteins, and mouse CXCR2 C-tail. (C), dosedependent (GST-NHERF1) macromolecular complex formation of His-Stagged PLC-β2 C-tail, GST-NHERF1, and HA-tagged human CXCR2. (D),
endogenous PLC-β2 and NHERF1 were co-precipitated with CXCR2 from
murine bone marrow neutrophils. Image taken from [1].
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3.4 CXCR2 C-terminal Synthetic Peptide
Formation of the CXCR2 macromolecular complex can be disrupted by delivery
of an exogenous biotin conjugated peptide which mimics the last 13 amino acids on the
C-tail of CXCR2 (biotin-FVGSSSGHTSTTL), thus competing with endogenous CXCR2
for PDZ-mediated binding of NHERF1. Our lab demonstrated this by a far Western blot,
which shows increasing amounts of CXCR2 binding to NHERF1, and inclusion of the
WT CXCR2 C-tail peptide disrupts the interaction, see Figure 3.5. Disruption of the
CXCR2 macromolecular complex, and CXCR2 dependent downstream activities, was
accomplished only by CXCR2 C-tail peptides containing the WT (wild type) PDZ motif.
In either mutation (AAA) or deletion (ΔTTL) variants of the CXCR2 C-terminal peptide
there was no difference compared to control cells, see [1]. Figure 3.6 illustrates the
nucleation of the CXCR2 macromolecular complex.

Figure 3.5 CXCR2 C-tail Peptide
A CXCR2 C-tail-specific peptide disrupts the physical interaction between NHERF1
and CXCR2. Binding of His-S-NHERF1 to 3HA-human CXCR2 in the presence of
human CXCR2 C-tail WT peptide on a Far Western blot. The membrane was
immunoblotted with HRP-conjugated S-protein, which detects S-tag within His-SNHERF1. Image obtained from [1].
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Figure 3.6 NHERF1 Nucleates CXCR2 and PLCβ2
Diagram depicting PDZ domain interactions of NHERF1 can nucleate
CXCR2 and PLCβ2 into a macromolecular complex, localizing receptor and
effector together for greater signaling efficiency. C-terminal PDZ-motifs are
STTL (CXCR2) and ESRL (PLCβ2).

3.5 CXCR2 Degradation
The NHERF1 scaffolding protein is involved in β2 adrenergic receptor (β2AR)
internalized sorting between the degradative-endocytotic pathway and receptor
recycling to the plasma membrane. A truncation of β2AR’s PDZ motif prevents NHERF1
binding, resulting in increased rates of receptor degradation. Furthermore, the
phosyphorylation of the P-2 serine (β2AR PDZ-motif is DSSL) inhibits NHERF1 PDZβ2AR interaction and affects intracellular sorting [233]. Similarly the C-terminal PDZ
domain of CXCR2 is required for efficient internal sorting of CXCR2, as loss of the PDZmotif affects receptor recycling [85].
I conducted a CXCR2 degradation assay to determine if the CXCR2 C-tail WT
peptide would interfere with receptor recycling. If the exogenous peptide affects
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receptor recycling, leading to degradation, CXCR2 stimulation could be greatly
diminished and could affect functional and migrational data. Degradation was assayed
by measurement of the total CXCR2 protein amount over a series of time points. As IL-8
binds to CXCR2 and activates signaling the receptor becomes internalized, see Figure
3.7.
Complications arose when trying to assay total cellular membrane protein
through a western blotting protocol as Western blots are not sensitive enough to small
shifts in protein amount. This is due in part to antibody binding, which is slightly erratic,
high levels of background noise, and incomplete transfers of protein to the PVDF
membrane. This assay was tested five times, and each gave a different outcome. Three
of the five provided quantifiable results and are displayed in the chart below. Also
provided is a Western blot image, which demonstrates some of the problems associated
with this procedure.
Based on the findings there is no significant change in CXCR2 levels over the
course of six hours in CXCR2 C-tail WT treated dHL-60 cells, compared to controls.
This indicates no excessive CXCR2 degradation due to the presence of CXCR2 C-tail
WT peptide. Further, this assures us that migrational data collected over the two hour
time period is due to interruption of PDZ domain binding and not a repressed level of
CXCR2. The CXCR2 degradation data shows a trend line average, which decreases
slightly as time passes for control and DEL (PDZ-motif truncation) samples, and
decreases more abruptly in CXCR2 C-tail WT delivered dHL-60 cells.
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Figure 3.7 CXCR2 Degradation
Cells are treated at various times with 100ng/ml of IL-8, a Western blot is
performed, and then probed for CXCR2. (A) Chart depicts trials of three
Western blot experiments. Average of all three in a given sample are green
bars, average error bars are based on the standard deviation, and moving
average is based on the last two average bars. (B) Image of a Western blot
depicting some problems associated with the experiment and data
acquisition, notice lower band intensity near the edges and incomplete
transfer of some bands.
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3.6 Migration Introduction
Targeting CXCR2’s PDZ domain which is four residues long gave a highly
specific site to focus on. In functional experiments interruption of the CXCR2 PDZdomain, through an exogenous CXCR2 C-tail peptide, affects downstream cellular
activity, see [1] for functional data. Disruption of complex formation represses CXCR2
calcium mobilization, a hallmark of PLCβ2 signaling [234]. Also, disrupting the NHERF1
PDZ-domain interaction with CXCR2 in dHL-60 cells inhibited GROα and IL-8
chemotaxis during transwell and thansepithelial monolayer migration. However, fMLP
migration was not disrupted in either assay, as bacterial proteins signal through
formylated peptide receptors. Following up on our previous paper [1], I further explored
dHL-60 cell migration to determine how CXCR2 type I PDZ-motif interactions affect
cellular migration and direction. The aim of my experiment was to characterize the
phenotypic difference between wild-type control cells and those delivered the CXCR2
C-tail WT peptide, described previously.
CXCR2 is distributed around the cell as a transmembrane protein and is bound
to NHERF1 forming a cytosolic signaling complex, which anchors the CXCR2 complex
on the cytoskeletal network. Disruption of NHERF1-CXCR2 PDZ-binding could free
CXCR2 from the cytoskeleton allowing chemokine signaling to be less stationary as
CXCR2 can laterally diffuse along the membrane. CXCR2’s resulting activity could be a
considerable distance away, and CXCR2 bound adaptor proteins (LASP-1, VASP,
IQGAP etc.) could spur actin mobilization in areas separate from the original stimulation
site. This would lead to a misrepresentation of the intracellular frontness signaling
against the extracellular IL-8 gradient. Also, if CXCR2 were unable to bind the NHERF1-
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PLCβ2 complex the receptor associated G-proteins would be further away from
downstream target PLCβ2. Therefore, G-protein signaling would be reduced, which
could explain the decrease in calcium mobilization observed, and this could further
hamper migration activities which are Gβγ dependent.
In the following Zigmond chemotaxis chamber experiment dHL-60 cells were
used, along with CXCR2 C-tail peptide derivatives, to assess the effects of CXCR2’s
PDZ interaction during chemotaxis. Six sample types of dHL-60 cells were used, two
control untreated cell types and four cell types treated with Chariot peptide delivery
system (with or without CXCR2 C-tail peptides). The two control untreated cell types are
dHL-60 cells supplied with (dHL+IL8) or without (dHL-IL8) an IL-8 chemokine gradient.
The positive control dHL+IL8 cells are expected to migrate uniformly towards the source
of the IL-8 gradient. The negative control dHL-IL8, which are not supplied an IL-8
gradient, are expected to show no directed movement and move at random.
All four Chariot treated sample types are supplied with a gradient of IL-8 and
treated with the Chariot peptide delivery system. The positive control group (CHAR)
contained no additional CXCR2 C-tail peptide, only the chariot delivery vehicle. Two
other experimental sample types were delivered either the CXCR2 C-tail WT peptide
(WT), or the CXCR2 C-tail PDZ-deletion peptide which was missing the three terminal
PDZ-motif amino acids (DEL). Based on the results of the previous study DEL samples
should behave similar to controls, whereas WT cells migration should be disrupted.
The last sample type is identical to the WT samples, delivered with CXCR2 C-tail
WT peptide and supplied an IL-8 gradient, but were also exposed to an opposing
gradient of fMLP (WT+fMLP). In this sample the intermediate target IL-8, which signals
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through CXCR2, should be overlooked for the end target fMLP bacterial derived
chemoattractant, which signals through FPR [206]. Therefore the CXCR2 C-tail WT
peptide should have no effect on the fMLP directed migration. This was observed, as
dHL60 cell function is inhibited by CXCR2 C-tail

T for GROα and IL8 but not fMLP

[1]. In all relevant sample types the IL-8 gradient was supplied from the downward
direction and fMLP was supplied from the top. My hypothesis is that the perturbing
CXCR2’s PDZ-motif binding interaction will disrupt the spatial sensation of a chemokine
gradient and impair cellular chemotaxis.

3.7 Distance Traveled

Figure 3.8 Distances Defined
The accumulated distance (Acc) refers to the total length of the path the
cell took to arrive at its endpoint. Euclidian distance (Euc) refers to the
distance between the endpoint and the origin, as demonstrated in the
figure.
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The data was divided into two portions, the control non-treated dHL-60 cells and
the dHL-60 cells treated with the Chariot peptide delivery system (Note: Samples
exposed to fMLP gradients were excluded from either group, as there were too many
variables compared to controls). The distance data between the two groups seemed
strikingly different at first glance, see Figure 3.8 and Table 3.1. Non-treated control
cells moved an average of 126.1um Euclidian distance (Euc) and 883.7um
Accumulated distance (Acc), while the peptide treated cells moved an average of
212.4um Euc and 1029.4um Acc. This amounted to only a 16.4% increase in
accumulated distance but a 68.4% increase in Euclidian distance. Since the
accumulated distance of all peptide delivered cells seems to be constant (20-30%
increase compared to dHL+IL8 cells, calculations not shown), the use of the Chariot
system might stress the cells, which could increase responsiveness through the
inflammatory/chemotactic response. Therefore the two types of conditions were
separated to analyze the distance data appropriately.
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Table 3.1 Distances Traveled
Distances of non-treated Control samples Vs. Peptide treated samples
This chart portrays the accumulated and Euclidian distances for the two
groups, highlighting the differences in distance between treated and nontreated samples.

Taking into account the non-peptide delivered control samples, see Table 3.2,
the accumulated distance is fairly similar with dHL-IL8 cells having ~14.6% more Acc
compared to dHL+IL8. But when Euclidian distance is considered, dHL-IL8 cells have
79.4% (20.6% less) Euclidian distance traveled than their counterparts, dHL+IL8 cells.
The Euclidian data is what is generally to be expected, as the negative control should
move in a less directional manner. Even though the dHL-IL8 Euclidian distance
decreased by only 20.6% the accumulated distance travelled by dHL-IL8 is 14.6%
greater, which makes it is safe to assume that if both cell types had travelled the same
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total accumulated distance the dHL-IL8 Euc deficit would be even greater. This is
evident when we take the directness (D= Euclidian/Accumulated distance) of the two,
Table 3.3. dHL+IL8 has a D=17.1% and dHL-IL8 has a D=11.8%. Comparing the two,
dHL-IL8 has only 69.3% of dHL+IL8’s directness (a 30.7% decrease). Therefore, dHLIL8 cells would have about ~30% less Euc corrected-distance than dHL+IL8 cells, which
is expected, given the dHL-IL8 sample has no chemokine gradient to migrate towards
but will still move randomly.
Looking at the group of Chariot-peptide delivered cells we see accumulated
distance compared to positive control CHAR is fairly similar, with DEL and WT samples
having a slight increase of 9.2% and 1.2% Acc distance, respectively, Table 3.2.
Euclidian distance shows DEL cells have 8.1% increase compared to CHAR, which
correlates closely to their 9.2% increase of Acc distance. Compared to CHAR, WT
samples show a 29.3% decrease in Euc distance, and comparing that with their 1.2%
increase in Acc gives an account similar to the D=30% decrease witnessed by dHL-IL8
vs. dHL+IL8. WT+fMLP group Acc is only 0.4% greater than positive control CHAR, yet
the Euc distance is increased 25.7%, which is significantly higher than the similarly
treated WT sample.
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Table 3.2 Distances Traveled Vs. Controls
Table depicts total accumulated and Euclidian distances for each sample
type. A comparison of negative control (dHL-IL8) or experimental samples
(DEL, WT, WT+fMLP) with their positive controls (dHL+IL8, CHAR) for each
group, respectively.

Comparing the directness to positive control CHAR, DEL has a D=98.9%, almost
identical, showing CXCR2 C-tail DEL-peptide has no substantial influence on migratory
directness, Table 3.3. WT has a D=69.8% compared to CHAR (30.2% decrease), which
is almost identical to the dHL-IL8 vs. dHL+IL8 data (30.7% decrease). WT+fMLP
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displays a high directness, D= 28.8%, and is 24.9% greater than CHAR samples. This is
most likely due to fMLP being an end target chemoattractant and stimulating a stronger
response in the neutrophil-like cells. This data demonstrates an endogenous CXCR2
PDZ-motif peptide disrupts directness of migration towards IL-8, a host produced
chemoattractant which signals through CXCR2, but does not disrupt directness of
migration towards bacterial derived chemoattractants.
Table 3.3 Directness
Directness of each experimental sample, based on total distance traveled,
compared to its positive control. The greater the directness, the more
linear (less random) the motion in a given direction.

3.8 Directness
Directness (D) is the quotient of Euclidian distance over the accumulated
distance (D=Euc/Acc). The samples directness through time is the average directness
of each cell in a sample at every time-point. Note: Directness is not a comparison of
compass direction; it is a comparison of distances travelled, the more direct (D=1) the
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straighter the path, the less direct (D=0) the more random the path. A cell chemotaxing
towards a gradient should display a higher directness than a cell migrating randomly.
Assessing the average directness requires distance data, thus the samples were
again divided, due to differences previously mentioned. Disregarding the WT+fMLP
sample for a moment, Figure 3.9 shows the control CHAR and DEL samples have the
highest overall directness towards IL-8, and are the two most direct moving sample
types with a D=0.25 and 0.22, respectively. The third most direct moving cell type was
the control dHL+IL8, D=0.19. WT cells started out with a high directness, but gradually
decreased, finishing at D=0.17, and the dHL-IL8 had the least direct movement, which
is expected from the negative control, D=0.13.

Figure 3.9 Directness Vs. Time
Average directness of each experimental sample throughout the 120
minute experiment. End target fMLP directed samples have the highest
overall directness, followed by positive controls, and negative control dHLIL8 have the lowest overall directness.
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Parallels can be drawn between the differences in directness of the two groups of
cells. dHL+IL8 has a higher end-value directness than the dHL-IL8 control (difference of
0.06), similarly CHAR has a higher directness than the WT sample (difference of 0.08),
while CHAR and DEL samples display more similar values (difference of 0.03).
Furthermore, WT+fMLP cells have the highest directed movement, compared to WT
there is a difference of 0.10, and only fMLP to account for the difference. An explanation
of the extremely high rate of directness in the beginning of the experiment might come
from the way in which directness is calculated; as time passes each cell has a greater
opportunity to turn, thereby changing the endpoint, and affecting the Euclidian distance,
but accumulated distance is always increasing. This is doubly true if the cell makes a Uturn and decreases its Euclidian distance while increasing the accumulated distance.
Since only moving cells were counted, and most move relatively straight for short
periods of time, their original few motions would have yielded high directness, until
turns, random movement, or directed migration patterns take over.
The difference in directed movement is evident when averaging the directness of
each group Table 3.4. The average percent directness of negative control dHL-IL8
compared to positive control dHL+IL8 is ~68%. Average directness of DEL or WT
compared to CHAR is ~89% and ~68% respectively. This is evidence that dHL-60 cells
in the presence of an IL-8 chemokine gradient simultaneously treated with a CXCR2 Ctail WT peptide migrate in a directed manner similar to negative control cells in no such
IL-8 gradient. Furthermore, the DEL treated cells lacking a competitive exogenous PDZmotif migrate similar to normal positive controls, and addition of an end target fMLP
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gradient restores directional migration in WT samples (WT+fMLP directness is 11.0%
greater than CHAR positive control).
Table 3.4 Average Directness
Average directness of all cells in a given sample. The directness is
compared to the positive controls, parallels can be drawn between the
negative control dHL-IL8 and WT treated samples.

3.9 Forward Migration Index
Forward migration index (FMI) is the distance travelled in a single plane, either
vertical (Y-axis) or horizontal (X-axis), see Figure 3.10. Where directness measured the
efficiency of migration without direction, FMIs measure the distance travelled either
horizontally or vertically from the origin. If a gradient is applied in one plane it’s average
forward migration towards or away from the source would give an account of the
sources attractive or repelling characteristics. An average migration in the other plane,
without a gradient, should be near zero because there are no attractive or repulsive
influences in said plane. If no gradient is established the average forward migration in
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both planes should be around zero, as average migration patterns should even out in an
adequate sample size. As you can see from Figure 3.11 the cells averaged 0.05 units
or less in horizontal movement from the origin. Since the IL-8 (or fMLP) gradient was
supplied vertically, seeing little horizontal movement is expected.

Figure 3.10 Forward Migration Indexes Defined
Schematic diagram showing the Forward Migration Index (FMI). FMI’s are
only observed on the X or Y axis. It measures how far horizontal or vertical
a cell has moved from the origin, as depicted by the green or red lines.
The Y-axis FMI is similar in dHL+IL8 and CHAR positive controls, which moved
down (negative Y-value) towards the source of IL-8, as did DEL samples. The only two
samples that did not have significant vertical movement were dHL-IL8 and WT cells,
see Table 3.5 and Figure 3.11. WT actually moved away from the gradient source,
whereas dHL-IL8 cells movement is completely random. Following the hypothesis, if WT
chemokine gradient sensation is disrupted then cells should exhibit more “random”
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motion compared to a direct one observed by the positive controls. Randomness in WT
samples, or absence of gradient in dHL-IL8 samples, is observed by noting that they
average almost no horizontal or vertical FMI (less than 0.02UNITS).Though, forward
migration was rescued in WT cells exposed to a fMLP gradient, as WT+fMLP samples
moved significantly towards the source of bacterial chemoattractant.
Table 3.5 Endpoint FMI’s
Endpoint X and Y-FMI of each sample, negative Y-values correlate to IL-8
mediated chemotaxis, positive Y-values correlate to fMLP mediated
migration.

Figure 3.11 Average FMI’s
Representation of each samples average FMI’s plotted on a graph. Average
downward migration correlates to IL-8 mediated chemotaxis, upward
migration is towards fMLP. There is no gradient on the X-axis plane,
therefore total X-FMI should be minimal.
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3.10 FMI Through Time
Looking at an average of each sample we can track the X-axis and Y-axis FMI
through time. These are displayed in Figure 3.12 and Figure 3.13. In each case the
opposite axis displays the time, each point plotted corresponds to 30sec and all 240
time-points total the two hours the experiment was executed. Considerations should be
made for the time it takes to establish a gradient, and the length at which the gradient is
effective before homogeneity. As previously stated, a vertical chemoattractant gradient
should cause the dHL-60 cells to move downward towards IL-8 (or upwards for fMLP)
and have no overall effect on the X-FMI. Likewise dHL-60 cells exposed to no
chemokine gradient should have little X or Y-axis FMI.
X-axis FMI, Figure 3.12, shows cells migrate to the left (negative X values) early
on, this is probably due to the side of the well the chemoattractants were added, when
the gradient is being formed. By roughly 20min most samples have tracked back to a
zero X-value, which it should theoretically have been from the onset, but does
demonstrate their sensitive perception of chemoattractants. Once the gradient is
established (roughly 20-30min) the cells do not travel far horizontally for the remainder
of the experiment.
The Y-axis FMI, seen in Figure 3.13, shows positive controls dHL+IL8 and
CHAR moving towards the negative Y-values through time. DEL cells behave similar to
the CHAR positive control with regard to an almost identical Y-axis FMI. dHL-IL8 and
WT cells stay relatively close to the Y axis (Y=0), which stated before, is expected in a
population of cells with random migration patterns. Although WT cells were provided an
IL-8 gradient they behaved strikingly similar to negative control dHL-IL8 cells. Once
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again we see forward migration can be rescued in WT cells by inclusion of a fMLP
gradient. This data directly supports the hypothesis, and points to a PDZ-motif
dependent disruption of CXCR2 chemokine-directed migration, which is undetected in
DEL samples, and rescued by an end target chemoattractant.

Figure 3.12 X-FMI Vs. Time
Each samples average X-FMI throughout the experiment. A strong pull
towards the left is initially observed as the gradient is being formed over
the first 20-30min. Gradients are depicted vertically.
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Figure 3.13 Y-FMI Vs. Time
Depicts each samples average Y-FMI throughout the experiment. Samples
should move towards their respected targets and random migration of the
negative control should be maintained near zero. Origins of the gradients
are depicted vertically.
3.11 Sector Maximum
Endpoints of each tracked cell are plotted along the X,Y axis. The sector
maximum is the direction (in degrees) in which the maximum number of endpoints falls
within a 60˚ interior angle. For all theoretical purposes any attractant gradient situated
along an axis should have a maximum sector at or near the angle value associated with
that direction. The counts inside and outside of the given 60˚ sector are given in the plot
along with the angle of greatest value.
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Sector maximum plots are shown in Figure 3.14. dHL+IL8 have a maximum
sector angle of 265˚, which is congruent with expectations of a gradient source situated
directly down. That trend is also observed in the CHAR cells which have a maximum
sector angle of 269˚. DEL samples are similar to the two positive controls with a sector
maximum angle of 279˚. This alludes to the fact that DEL cells distribute nearly identical
to controls when exposed to a chemokine gradient. dHL-IL8 on the other hand shows
no such congruence to positive controls, which should be expected in a gradient
deficient control group. The dHL-IL8 sector maximum is 44˚, which coincides with dHLIL8 having a high presence of endpoints in the first quadrant.
WT cells also experienced a sector maximum angle in the first quadrant. The WT
maximum sector angle is 78˚, almost 180˚ opposite the gradient supplied. Because the
WT cells were exposed to the same gradient as the positive controls it must be
concluded that the CXCR2 C-tail WT-peptide disrupted the directional sensation of IL-8.
CXCR2 signal disruption caused WT samples to move randomly, similar to negative
control dHL-IL8. The sector maximum for WT+fMLP samples is 98˚, which coincides
with their fMLP gradient situated straight up, away from the IL-8 source, demonstrating
that CXCR2 C-tail WT peptide does not disrupt fMLP migration in dHL-60 cells.
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Figure 3.14 Sector Maximum
Green vectors identify the sector maximum, a 60˚ angle. Counts inside and
outside of the vector, along with the angular degree are given in each plot.
Cells that end in negative Y-values are red, positive Y-values are black, and
the center of mass is depicted as a blue (+).
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3.12 Rose Diagram
The chemotaxis tool in ImageJ supplies a variety of tools to visualize migration
data. One diagram that is easily interpreted is the rose diagram, see Figure 3.15. In this
assessment the migration endpoints are used in a quantitative manner to analyze
overall directional movement in a 360˚ circle. The diagram is comprised of individual
vectors placed every 10˚, 36 vectors total. Each vectors size is equal to the quantity of
endpoints in that vectors particular range. The total range for each vector is 30˚. This
means each vector’s size comprises of the endpoints within +/- 10˚ either side of the
vector.
Positive control samples dHL+IL8 and CHAR show their biggest vectors pointing
downward along the Y-axis, towards the source of IL-8 and higher gradient
concentration. The rose diagram for DEL cells looks almost identical to the CHAR cells
and also points directly downward. dHL-IL8 has the highest vector values in the first
quadrant between 0˚ and 90˚, since there was no gradient or chemokine applied to the
dHL-IL8 samples it is assumed they would migrate randomly and form a pseudo circle
around the origin, which is roughly represented. The WT samples also move in a similar
way, forming a pseudo circle around the origin. The first three quadrants account for a
majority but the overall shape is analogous to the negative control (dHL-IL8). The
WT+fMLP rose diagram points straight up showing the WT+fMLP sample moved toward
fMLP in a directed manner.
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Figure 3.15 Rose Diagrams
An easy to interpret diagram of each samples endpoint distribution. Each
vector spans a 10˚ angle and comprise of endpoints within a 30˚ angle (+/10˚ on either side). Vector size represents the total number of endpoints
within each 30˚ range.
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3.13 Center of Mass
The center of mass (COM) shows an average of the cells positions in a given
sample throughout the 120 minute experiment, Figure 3.16. Direction and distance
have a factor in determining the center of mass. This data provides an excellent account
of the average pattern in which samples migrated. The center of mass resembles the
average FMI values of each sample and the FMIs observed through time. It also
correlates well with the rose diagram and sector maximums.

Figure 3.16 Center of Mass Vs. Time
Average center of mass of each sample can be used to determine the
majority of cell movement in a given sample. The COM is depicted by a
path corresponding to each sample throughout the experiment.
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Table 3.6 COM Distance From Origin
Each samples COM distance from the origin and degree deviation from the
Y-axis. Angles were calculated using the COM end point and basic
trigonometry: Sin() = Opposite / Hypotenuse, Cos() = Adjacent /
Hypotenuse, Tan() = Opposite / Adjacent, distances are calculated “as the
crow flies” by the same trigonometric equations.

Positive controls moved similarly, dHL+IL8 and CHAR COMs moved toward the
higher IL-8 gradient, 51.8um and 127.4um respectively, and strayed little from the Yaxis, 7.57˚ and 4.95˚ respectively, Table 3.6. DEL sample’s COM moved very similar to
the positive control types, 143.67um, and only strayed 2.2˚ from the Y-axis, which
shows a strong COM movement toward IL-8. dHL-IL8 sample COM moved away from
the origin at a 46.24˚ angle, and migrated only 18.12um total. The dHL-IL8 COM data
indicates no chemoattractant gradient was formed, as there would be planar movement
in a unilateral manner. Instead dHL-IL8 moved a negligible distance in both X and Y
planes.
WT cells COM most closely resemble dHL-IL8 negative control, moving a total of
24.22um and 20.4˚ off the Y-axis. Although the WT sample’s COM moves almost three
times further vertically than horizontally, the vertical distance is minor compared to
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positive controls. Furthermore, the direction of WT’s COM is almost exactly opposite the
IL-8 gradient supplied. Lastly, the WT+fMLP samples COM moved significantly upward
263.39um, and only 11.86˚ off the Y axis, showing the strongest collective movement
toward a chemokine of any sample.

3.14 Rayleigh Test
The Rayleigh test is a statistical test for determining if a circular distribution of
objects is random or uniform. With p-values >0.05 the null hypothesis (uniformity of
direction) is rejected. The Rayleigh test is strongly dependent on the number of samples
(n) being analyzed in a group, and the Rayleigh test for vector data also incorporates
the distance from the origin, see Table 3.7. The Rayleigh test can be used in
conjunction with a rose diagram (or the sector maximum for an angular value) to give
direction to statistically relevant data of each group.
Rayleigh test for dHL+IL8 positive control samples shows that they migrated in a
uniformly directional manner p=3.72E-04, coupled with the sector maximum (265˚) this
data statistically demonstrates that dHL+IL8 uniformly responded to the chemokine
gradient. CHAR positive control sampled cells also show a uniform distribution,
p=2.44E-06. Again, by using the statistical data and an angle measure of the sector
maximum (269˚), we can come to the conclusion that CHAR cells uniformly responded
to the IL-8 gradient. DEL cells have the lowest p-value of the IL-8 treated groups,
p=4.40E-10, which indicates they distributed in an exceedingly uniform manner. The low
DEL p-value is partly due to the higher sample size and congruency of distribution. The
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DEL p-value and sector maximum angle (279˚) also concludes that DEL samples
distribute uniformly to the IL-8 chemokine gradient.
On the other hand dHL-IL8 cells have the highest p-value, p=0.160, which
assures us that the negative control dHL-60 cells are distributed in a random manner.
This is the expected outcome from cells lacking a gradient to chemotax towards and
assures the previously stated negative-control data is relevant statistically, i.e., the data
is random. WT samples also demonstrate random migration, p=0.153. This indicates
the sector maximum data, or any other data for that matter, is not relevant in statistically
determining which direction the WT sample would migrate. But, when WT treated
samples are exposed to fMLP uniform distribution is rescued, p=1.436E-28. Taking the
sector maximum data into account, WT+fMLP samples moved in a statistically relevant,
highly uniform, manner towards their end target chemoattractant.

Table 3.7 Rayleigh Test
Displays each samples number of cells (n), and statistical p-value for the
Rayleigh test and Rayleigh test for vector data (from the chemotaxis tool
ImageJ plugin). A p-value of >0.05 corresponds to random distribution,
whereas a p-value <0.05 corresponds to uniformity.
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CHAPTER 4
DISCUSSION

4.1 Conclusion of Biochemical Data
The data presented in Figures 3.4 and 3.5 were collected through my advisors
laboratory with only partial contribution from me. I added this data into the results
section to convey the graduation of experiments and knowledge in a comprehensive
format. I do not take credit for their work.
Assessment of protein expression in differentiated HL-60 cells was important, as
they can be directly compared to naturally derived neutrophils. Determining NHERF
expression in dHL-60 cells is significant since NHERF2 competes with NHERF1 for
binding of CXCR2 and PLCβ2’s PDZ-motifs. Western blot data shows NHERF1 is the
primary isoform expressed in dHL-60 cells and NHERF2, was not detected in dHL-60
cells. This rules out possible binding of CXCR2’s or PLCβ2’s PDZ-motifs by
endogenous NHERF2, which if expressed at exceedingly high rates could compete for
PDZ-motif binding sites with NHERF1. Western blotting also found PLCβ1 is absent in
dHL-60 cells, PLCβ2 is the main isoform expressed in dHL-60 cells, and PLCβ3 is
expressed at a much reduced level. This data is consistent with observations of human
neutrophils, which use PLCβ2 as the major isoform in chemokine signaling, and have
minor activity from PLCβ3 [229-231]. NHERF2 interacts specifically with PLCβ3 and
both of these proteins are expressed at extremely low levels in dHL-60 cells [235].
Therefore it can be postulated that NHERF2 or PLCβ3 do not play a significant role in
CXCR2 signaling. This data confirms proteins involved in CXCR2 scaffolding and
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signaling, namely NHERF1 and PLCβ2, are similar in dHL-60 cells and human
neutrophils, as expected.
Through a GST-tagged scaffolding protein pulldown we demonstrated human
and murine CXCR2 and PLCβs all bind to NHERF proteins, though this interaction is
mainly facilitated by NHERF1. By using His-S-tagged C-tails of both CXCR2 and PLCβ2
we found a CXCR2 macromolecular complex can be formed consisting of CXCR2,
NHERF1 and PLCβ2. Using purified proteins meant the complex formation is
independent of other cytosolic factors and we further exemplified this by pairwise
binding between CXCR2 and NHERF1. Also CXCR2 macromolecular complex was
found in vivo from isolated mouse bone marrow neutrophils. Lastly, to interrupt the PDZmediated binding of this complex a synthetic peptide, which replicates the last 13
residues of CXCR2, was produced. This PDZ-motif containing peptide inhibits complex
formation, as seen in the far Western blot, by competing with endogenous CXCR2.
Further studies linked PDZ disruption to suppression in CXCR2 functional activity, such
as calcium mobilization and transepithelial migration [1].
The CXCR2 degradation experiment showed no significant data. What can be
inferred is the total amount of CXCR2 is not diminished to undetectable levels. This in of
itself is somewhat valuable as CXCR2 must be available for signaling activity and
migrational data is not corrupted due to an excessive lack of chemokine receptor.
Based on the average trend line data, it seems plausible that a CXCR2 C-tail WT
peptide could interfere with receptor recycling and increase degradation, however,
Western blotting is an inappropriate assay to determine this. If this experiment should
be conducted again, FACS (fluorescence activated cell sorting) should be considered.
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This method would employ a highly sensitive flow cytometer to measure cell surface
CXCR2 levels through a fluorescence conjugated antibody.
In conclusion, dHL-60 cells represent viable alternatives for human neutrophils in
the context of CXCR2 NHERF proteins and PLCβ isoforms. CXCR2 and PLCβ2 both
interact with NHERF1 through a PDZ dependent interaction and together they form a
macromolecular complex. This complex links CXCR2 and its downstream effector
PLCβ2 through the actin binding scaffolding protein NHERF1. Furthermore, an
exogenous CXCR2 C-tail synthetic peptide can disrupt the complex formation and
repress CXCR2 functioning [1]. This peptide might also disrupt intracellular sorting of
CXCR2, although more clarification is needed.

4.2 Conclusion of Migrational Data
Accumulated distances suggest that both dHL-IL8 and WT samples migrated
analogous to positive controls, yet their directness was roughly 30% less. The WT
samples were exposed to a 50ng/ml gradient of IL-8, whereas dHL-IL8 experienced no
such gradient. The DEL samples directed their migration similar to the positive controls
and the only difference between DEL and WT samples is the inclusion of a synthetic
CXCR2 type I PDZ-motif. Furthermore, migrational directness was reestablished when
WT samples were exposed to a fMLP gradient. Therefore, it can be inferred the
exogenous PDZ-motif is responsible for the disruption of IL-8 mediated directness of
migration. Disrupting CXCR2 PDZ-domain interactions caused dHL-60 cells exposed to
an IL-8 gradient to direct migration similar to dHL-60 cells experiencing no IL-8 gradient.
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The forward migration index assays the movement on the X or Y-axis. As
expected, the control samples and WT+fMLP all have significant Y-axis FMI’s. Negative
control dHL-IL8 has little X or Y-axis FMI and this display of random movement is also
observed in WT samples. The FMI data supports the hypothesis that the WT sample
seems unable to recognize the direction of a gradient. DEL samples enforce the
importance of PDZ binding disruption and confirm forward migration is not disrupted
with the inclusion of a CXCR2 C-tail peptide lacking the PDZ-motif. Data from the sector
max, rose diagram and center of mass further exemplify the contrast between DEL and
WT samples. Data shows general distribution of dHL+IL8, CHAR and DEL samples
towards the chemokine gradient, with the greatest abundance along the negative Yaxis. Meanwhile dHL-IL8 and WT samples show a high degree of random movement
and are evenly dispersed around the origin. Yet, inclusion of a fMLP gradient restored
normal distribution in the WT samples, due to fMLP signaling through FPR, not CXCR2.
The Rayleigh test statistically confirms these findings. DEL samples distribute
uniformly to the IL-8 gradient, akin to positive controls. WT samples, like negative
control dHL-IL8, do not distribute uniformly and exhibit statistically random migration.
Importantly, exposure to fMLP rescues directional chemotaxis in WT treated cells. It is
worthwhile to note that the WT accumulated distance was comparable to the positive
controls and DEL or WT+fMLP directed migration was not disrupted. This establishes
that CXCR2’s PDZ-motif interaction, however important in chemokine directional
sensation, does not play a key role in moving the cell forward. But, whether or not
disrupting CXCR2 nucleation into a macromolecular complex affects anchoring of
CXCR2/actin modulating proteins (Arp2/3, VASP, LASP-1, IQGAP, etc.), sustaining the
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leading edge, or possibly disrupts other PDZ interactions (NHERF2-PTEN), has yet to
be determined.
In summary, Zigmond chemotaxis chamber migrational data confirms significant
differences between the two experimental samples. dHL-60 cells migrated as expected
and delivery of the CXCR2 C-tail peptide containing the PDZ-motif severely repressed
IL-8-mediated chemotactic migration. Also, the CXCR2 C-tail peptide lacking the PDZ
motif had no effect on overall migration, which rules out residues in the CXCR2 C-tail
peptide affecting chemotaxis. Therefore, it can be concluded that PDZ motif-domain
interactions play an important role in directing dHL-60 cells during CXCR2/IL-8mediated chemotaxis, and disruption of PDZ-mediated CXCR2 macromolecular
complex formation abolishes spatial sensation in a chemokine gradient. The data
collected from the Zigmond chemotaxis chamber verifies the hypothesis, that perturbing
CXCR2’s PDZ-motif binding interaction will disrupt spatial sensation of the chemokine
gradient and impair cellular chemotaxis, is correct.

4.3 Thoughts
Excessive infiltration of neutrophils is the cause of many inflammatory diseases
[17]. As neutrophils infiltrate into tissue the surrounding area is subjected to a variety of
proteolytic enzymes and reactive oxygen species deployed by neutrophils to combat
infection, which causes extensive tissue damage and delays wound healing [236, 237].
Yet their role in bacterial clearance remains imperative to host pathological defense
[238]. When searching for a therapeutic approach to combat auto-inflammatory disease

75

a balance must be reached, in order to provide anti-inflammatory relief, without
compromising a legitimate immune response.
Some therapeutic methods (neutralizing antibodies or small organic compounds)
utilize an extracellular antagonist of CXCR2 to allosterically or competitively disrupt
chemokine binding [239]. In either case, the effect is a complete inhibition of the CXCR2
signaling cascade and buildup of IL-8, which cannot be scavenged by receptors [240]. A
systemic shutdown of CXCR2 would suppress the hosts ability to initiate an immune
response, induce angiogenesis of endothelial cells, or begin wound healing after injury
[241]. The data presented in our recent report [1] and this report target a specific
peptide motif in the cytosol and represents a novel strategy to disrupt CXCR2 mediated
signaling without complete blockade of the signaling system. Disruption of CXCR2-PDZ
domain interaction still allows IL-8 binding, receptor internalization, and a diminished
chemokine response [1]. Yet, chemotaxis towards host derived inflammatory
chemokines becomes impaired, leaving the cells unable to spatially detect a gradient,
while chemotaxis towards bacterial peptides (fMLP) remains normal.
Tissue damage caused by sterile injury exhibits damage associated molecular
patterns (DAMPS), derived from human mitochondria, which attract neutrophils through
formylated peptide receptors [242]. Additionally, a study of CXCR2-/- mice showed they
have no impairment in clearance of bacteria, as mouse neutrophils could utilize other
means to reach their targets [243]. This represents evidence for CXCR2-PDZ disruption
not interfering in sterile injury or bacterial related inflammatory responses, while
providing a therapeutic target for chronic/hyper inflammatory diseases derived from
excessive chemokine production.
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4.4 Future Directions
The goal of disease associated research is to understand the mechanisms
involved, and use this knowledge for therapeutic development. One major facet of
developing therapeutics should focus on the consequences of globally or locally
disrupting CXCR2’s PDZ-motif interaction. This would hinge on the discovery of a drug
or soluble molecule to disrupt CXCR2 cytosolic PDZ-motif interactions, replicating the
effects of the CXCR2 C-tail WT peptide used. Drug discovery is by no means an easy
task and may not become feasible or fruitful but, if such a compound exists, could prove
beneficial in research of autoimmune diseases. Although there is no account of the
effects PDZ-domain disruption would cause in other areas of the body, as PDZ domains
occur frequently and their disruption could pose problems in distal locations.
Therefore, in vivo experimentation should be considered an obtainable goal.
Murine air-pouch models or those mimicking human inflammatory diseases should be
assessed for viability and executed. This would require genetically modified mice (or
another animal model), with mutation of the CXCR2 PDZ-motif. Although, truncation of
CXCR2 PDZ-motif is not identical to a soluble drug, any in vivo results should be more
in

line

with

actual

biological

systems.

By

cytosolically

targeting

CXCR2’s

macromolecular complex formation, new therapies can be developed, opening the door
to innovative opportunities in similar systems.
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ABSTRACT
DISRUPTING CXCR2 MACROMOLECULAR COMPLEX PDZ-DOMAIN
INTERACTIONS DURING INFLAMMATORY CHEMOTAXIS
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Neutrophils are the body’s first responders to inflammation being the most
abundant white blood cell type in circulation and they quickly initiate an immune
response through chemokine signaling. Inflammatory chemokines signal via their
receptor CXCR2, which initiates an inflammatory response, recruiting leukocytes to
sites of inflammation. Chemokine signaling is important for proper host protection, yet
uncontrolled activity is responsible for a variety of pathological conditions: including
rheumatoid arthritis, ischemia-reperfusion injury, arteriosclerosis, multiple sclerosis,
psoriasis, inflammatory bowel disease, and allergic reactions.
In this report I show a CXCR2 macromolecular signaling complex exists in
neutrophils containing NHERF1 and PLCβ2. I also demonstrate a novel strategy of
cytosolically perturbing the CXCR2 PDZ-domain interaction of the macromolecular
complex. This perturbation disrupts spatial sensation of a chemokine gradient, yet still
allows cells to mobilize actin and chemotax. Furthermore, I show CXCR2 PDZ-domain
perturbation does not disrupt migration through bacterial derived chemoattractant
receptors.
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